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Abstract 
The MDM2 protein, a p53 inhibitor, is involved in cell cycle control and 
apoptosis. MDM2 may promote tumorigenesis when over expressed, 
amplified or mutated. The expression of MDM2 has been shown to be 
modified by some functional single nucleotide polymorphisms (SNPs). 
SNP309, a T → G transversion, is localized to position 309 in the MDM2 
P2 promoter. An association between SNP309 and lung cancer has been 
reported. However, there is no functional data for this SNP in human lung 
cells. In this project the MDM2 P2 promoter activity with T/T or G/G 
SNP309 genotypes in human lung cells was characterized. Two luciferase 
reporter vectors containing the SNP309/P2 region (SNP309-T/G-Luc) were 
constructed and transfected into human lung cells. Since MDM2 has been 
associated with an increased risk of cancer in women and has been 
reported to interact with estrogen receptors, SNP309 estrogen 
responsiveness was also investigated. This was done by exposure of the 
SNP309-T/G-Luc-transfected cells with 17β-estradiol. 
SNP309-T/G-Luc transcriptional activity was significantly higher with the 
T/T genotype in lung cell lines. To rule out a tissue specific effect, cell 
lines derived from breast, colon and cervix were investigated. 
Consistently, the SNP309-T/T-Luc reporter vector had a higher 
transcriptional activity. Estrogen exposure in 4 human lung cell lines 
showed no significant effect on transcriptional activity. Still, the T/T 
genotype showed a higher transcriptional activity, except in one cell line 
where there was no difference between the two genotypes. A trend 
indicating a decreased transcriptional activity for G/G in the female lung 
cancer cell line NCI-H2009 was observed. For SNP309 further elucidation 
of interacting factors and possible linkage with other SNPs, need to be 
investigated. 
A second functional SNP, C1797G, in the MDM2 P1 promoter was 
recently identified and shown to affect MDM2 mRNA levels. An 
association between C1797G and risk for bladder cancer has been 
observed. The role of this polymorphism in susceptibility to lung cancer 
has not been investigated. In this project its association with lung cancer 
in a panel of lung cancer patients and healthy controls from Norway was 
investigated. The results showed a possible protective effect for lung 
cancer in C1797G heterozygote subjects after adjustment for age, sex and 
smoking. This effect was only seen for female smokers and was 
statistically significant indicating a gender-specific effect. Functional 
studies of this SNP should be performed to investigate the underlying 
mechanisms for the observed protective effect. 
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Abbrevations 
Amp
R
 ................................................... Ampicillin resistance 
ANOVA ............................................... Analysis of variance 
Apaf-1...................................... Apoptosis activating factor 1 
ARF .............................................. Alternative reading frame 
ATM ....................................... Ataxia telangiectasia mutated 
ATP ................................................. Adenosine triphosphate 
B(a)P............................................................. Benzo(a)pyrene 
Cdk ................................................. Cyclin dependent kinase 
cDNA ................................................. Complementary DNA 
ChiP .................................... Chromatin immunoprecipitation 
CI ............................................................ Confidence interval 
CYP ............................................. Cytochrome P450 oxidase 
Cyt c ................................................................ Cytochrome c 
ddNTP ...................... Dideoxy ribonucleotid 5’-triphosphate 
DNA .................................................. Deoxyribonucleic acid 
dNTP ......................... Deoxy ribonucleotide 5’-triphosphate 
dsDNA…………………………..Double stranded DNA 
E.coli ........................................................... Escherichia coli 
EMSA ........................................ Electro mobility shift assay 
ERα .................................................. Estrogen receptor alpha 
ERβ .................................................... Estrogen receptor beta 
EtBr .......................................................... Ethidium bromide 
G1 ....................................................................... Gap 1 phase 
G2 ....................................................................... Gap 2 phase 
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HAUSP..Herpes virus associated ubiquitin spesific protease 
IARC ............. International Agency for Research on Cancer 
LAF ............................................................ Laminar air flow 
LB..................................................................... Luria-Bertani 
LB-amp ................................. Luria-Bertani with Ampicillin 
Li Fraumeni ..... Individuals with germ line mutations in p53 
M……………………………………………………..Molar 
M phase ............................................................ Mitotic phase 
MDM2 ............................................. Murine minute double 2 
ml…………………………………………………Milliliters 
mmol………………………………………………Millimol 
mRNA ........................................ Messenger ribonucleic acid 
NaOH ....................................................... Sodium hydroxide 
NCBI .......... National Center for Biotechnology Information 
Neoplastic .............. Abnormal growth/accumulation of cells 
NES ..................................................... Nuclear export signal 
NIOH…………..National Institute for Occupational Health 
NLS ............................................. Nuclear localization signal 
NoLS ........................................Nucleolar localization signal 
NSCLC ....................................... Non-small cell lung cancer 
OR ......................................................................... Odds ratio 
P1 ............................................................ MDM2 promoter 1 
P2 ............................................................ MDM2 promoter 2 
P3……………………………………….MDM2 promoter 3 
PAH .................................. Polycyclic aromatic hydrocarbon 
PCR ............................................. Polymerase chain reaction 
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Rb ................................................................. Retinoblastoma 
RFLP ................. Restriction fragment length polymorphism 
RNA ........................................................... Ribonucleic acid 
rpm ................................................... Revolutions per minute 
S.. ............................................................................... S phase 
SCLC .................................................. Small cell lung cancer 
SDS................................................ Sodium dodecyl sulphate 
SE ................................................................... Standard error 
SNP.................................... Single nucleotide polymorphism 
ssDNA ..................................................single stranded DNA 
SUMO .................................... Small ubiquitin-like modifier 
SV40 ........................................................... Simvian virus 40 
UV ........................................................................ Ultraviolet 
µg ......................................................................... Microgram
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1. Introduction 
1.1 Lung cancer 
Lung cancer is one of the leading causes of cancer death and is often 
associated with exposure to carcinogenic substances [1]. Lung cancer can 
be divided into two major categories: small cell lung cancer (SCLC) and 
non-small cell lung cancer (NSCLC). NSCLC can be further divided into 
squamous cell carcinoma, adenocarcinoma and large cell carcinoma [1].  
Both in men and women, lung cancer is now the third most common 
cancer form in Norway. In females, lung cancer incidence has increased 
over the last years with 7,3 %  in 1978-1982 to 21,8 % in 2002-2006 but 
the incidence in men has gradually decreased since the 1990s. In 2004, 
there were 10 500 cancer deaths in Norway where lung, colorectal, 
prostate and female breast cancers were responsible for about half of 
these [2].  
Lung cancer etiology is well established and thus lung cancer is a useful 
model when studying gene-environment interactions. Furthermore it is a 
good model to study the molecular mechanisms underlying carcinogen-
induced tumors [3].  
1.2 Lung function and physiology  
The principal functions of the lungs are ventilation, perfusion (delivery of 
arterial blood to the capillary bed in the lungs) and diffusion. The gas 
exchange takes place in the alveolar space with diffusion of oxygen and 
carbon dioxide over the epithelium. Lungs are exposed to toxic substances 
by two routes; inhalation or by the bloodstream [4].  
Inhaled particles are deposited in the airways according to size, shape, 
density and water solubility (also for gases). Highly water soluble 
gases/particles deposit early in the respiratory system and become 
relatively non-toxic. Insoluble gases/particles such as O3 and NO2 
penetrate deep into the alveolar space where they can elicit a toxic effect. 
If the gas/particle is extremely water insoluble it can cross the epithelial 
surface and possibly be taken up in the bloodstream to exert its toxicity in 
other locations. Some effects of toxic substances can be 
bronchoconstriction, increased proliferation of defense cells, fibrosis, 
asthma and lung cancer. There are many substances known to cause both 
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acute and chronic damage to the lungs. Some of these are metals, fibers 
(i.e. asbestos), coal and cotton dust, inorganic compound such as ammonia 
and hydrogen fluoride, nitrogen oxides and ozone. These give rise to 
oxidative damage, DNA adducts and direct physical damage [4].  
1.2.1 Some lung damaging substances  
Asbestos is a silica fiber and comes in several forms. Exposure occurs in 
mining and construction industries where asbestos once was widely used 
due to its insulating and fireproofing properties. It can give rise to 3 types 
of lung disease: asbestosis (similar to fibrosis), lung cancer and malignant 
mesothelioma. Macrophages release inflammatory mediators such as 
cytokines and interleukins in response to the fibers. This leads to 
additional stress on the lung with additional collagen production and 
damage caused by reactive intermediates which can lead to cancer [5].  
Free radicals are made by loosing or gaining an electron or by homolytic 
fission of a covalent bond. Several chemicals, for example Paraquat, can 
give rise to free radicals and then often by transferring electrons to 
molecular oxygen, forming radicals and then restoring the parent 
xenobiotic (redox cycling). These radicals are also produced endogenously 
as intermediates during enzymatic activity, during detoxication of 
xenobiotics and during inflammation. Free radicals have been shown to be 
involved in chemical carcinogenesis and induction of inflammation. In 
addition they may interact directly with DNA to give rise to several 
structural changes in the nucleotides or DNA strand [5,6].  
Polycyclic aromatic hydrocarbons (PAHs) are found in tar and coal 
deposits as well as being formed during incomplete combustion of organic 
matter and fossil fuels. Humans are exposed mainly by pollution from 
traffic, burning of waste, burning of fuel/gas and by consumption of 
grilled/smoked food. PAHs are a group of structurally related compounds 
consisting of aromatic, benzene like, carbon rings. PAHs can also contain 
unsaturated rings with 4, 5 or 6 hydrocarbons. These rings may be 
substituted with different chemical groups such as alkyl, amino, halogen 
or nitro groups which will alter the chemical and toxic properties of the 
compound [7,8].   
One of the biomarkers for exposure to PAHs is the concentration of 
benzo(a)pyrene (B(a)P) in an organism [9]. As an example of detoxication, 
B(a)P metabolism is shown in figure 1-1. 
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Figure 1-1: The biotransformation of benzo(a)pyrene showing different 
metabolic outcomes depending on positioning of the initial hydroxyl 
group. AKR; aldoketo reductase. P450; Cytochrome P450 oxidase. 
Modified after Casarett and Doull's Basic science of Poisons [5]. 
B(a)P is a good example of how intermediates can become carcinogenic 
and that there are several outcomes of the detoxifying process [5]. 
Exposure to cigarette smoke is one well known factor that often leads to 
lung damage and cancer. The smoke emerging from the mouthpiece of a 
cigarette contains approximately 4800 compounds of which 60 have been 
classified as carcinogens by the International Agency for Research on 
Cancer (IARC). These include, among others, PAHs, nitrosamines, nickel, 
cadmium, ethylene oxide and all are shown to induce lung tumors in at 
least one animal species. Cigarette smoke also contains free radicals and 
induces oxidative damage in the lung. In addition, NO and other oxidants 
from cigarette smoke contribute to oxidative damage [10]. In figure 1-2 an 
overview of cancer development in smokers is shown.  
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Figure 1-2: Cancer development during chronic exposure to cigarette 
smoke. The different detoxifying steps and how the pre-neoplastic lesion 
develops during prolonged cigarette smoke exposure. Modified after 
Pfeifer et al [10]. 
Tobacco smoke carcinogens, and other carcinogens, can be metabolically 
activated by detoxifying enzymes (usually cytochrome P450 oxidase 
(CYP)). Metabolites can interact with DNA to form DNA adducts. These 
adducts may lead to miscoding, mutations and possibly cancer if the 
adducts escapes the repair mechanisms [11]. Lung cancer is a disease 
where 80 % of the cases are attributed to smoking. In contrast only about 
15 % of smokers get this illness [12]. Both primary and second hand 
cigarette smoke exposure is associated with lung cancer, though with 
different relative risk. The risk of developing lung cancer decrease after 
smoking cessation [11].  
1.2.2 Phase I and II detoxifying enzymes 
To detoxify xenobiotics cells have evolved phase I and II metabolizing 
enzymes. Phase I biotransforming enzymes are oxidases where CYP is one 
of the most active and have numerous substrates. CYP is also involved in 
the metabolism and possible activation of xenobiotics and other 
carcinogenic compounds. Endogenously, CYP is amongst other involved in 
the biosynthesis of steroid hormones, bile acids, fat-soluble vitamins and 
fatty acids. CYP catalyzes the addition of an oxygen atom to the toxic 
compound to increase its water solubility and simplify excretion. This 
detoxication and excretion process is, if needed, further aided by phase II 
conjugating enzymes. Phase II enzymes attach conjugates that will 
further detoxify the compound. An example of phase II enzymes is 
glutathione transferases which are located in the cytoplasm in most cells. 
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Glutathione transferases catalyses the addition of glutathione (a 
tripeptide) to an electrophilic atom (O, N, S or C) in the xenobiotic 
molecule. The negative side of the detoxifying process is that some of the 
intermediates produced are reactive and usually have electrophilic 
centers. These can interact with nucleophilic DNA and proteins leading to 
adduct formation and cell damage [5,10,13].  
1.3 Estrogen and lung cancer  
An increase in lung cancer incidence in females has been seen. This has 
lead to an increase in the focus on estrogen involvements in lung cancer 
development. Estrogen affects the growth, differentiation and function of 
several cell types in both males and females. NSCLC cells have been 
stimulated to proliferation in vitro by estrogen. It has been suggested that 
estrogens are direct carcinogens after metabolic activation to catechol 
(possible mutagenic and DNA adduct formation) and may be directly 
involved in carcinogenesis by promoting cell proliferation and altering the 
metabolic activation of carcinogens [1,14,15].  
Estrogen has two receptors in humans: estrogen receptor alpha (ERα) and 
estrogen receptor beta (ERβ). The receptors have different tissue 
distribution and ERβ is the predominant receptor found in lung tissue. 
ERα and ERβ have been suggested to have opposite functions, 
proliferative and non-proliferative respectively. ERα is more likely to be 
expressed in lung tumors in females than in men [14-17]. When estrogen 
binds to ERs the resulting complex functions as a transcriptional activator 
of specific estrogen responsive genes. The ligand-ER complex can also 
interact with other transcription factors. Upon binding their ligand ERs 
go through conformational changes that will engage the transcription 
machinery and/or locally affect the chromatin structure to regulate 
transcription [5,14].  
ERs may interact with several genes involved in carcinogenesis. An 
association between the p53 inhibitor MDM2 (minute double murine) 
over-expression and ERα expression has been reported. Further, Saji et al 
has shown that MDM2 enhances the transcriptional activity of ERα [15]. 
1.4 Gentic suceptibility and risk of lung cancer 
Different individuals have different susceptibilities to disease. Some of 
these differences are believed to be the cause of heritable traits that 
modify the effect of environmental exposures [12]. Possible host factors 
involved in susceptibility are the balance between phase I and phase II 
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detoxication of carcinogens and the individual’s capacity to repair DNA 
damage. In addition there are multiple common low-penetrance (low risk) 
gene alleles in the general population which are associated with small 
increases in individual risk. These contribute considerably to overall lung 
cancer risk in the population.  
More than 10 million genetic variants exist and they are divided into 2 
major groups: tandem repeats and single nucleotide polymorphisms 
(SNP). Tandem repeats are a collection of successive repeats of various 
lengths. A SNP is where the same nucleotide position can have several 
different genotypes in the population. The less common genotype 
variation must be present in 1 % or more of the population to be 
characterized as a SNP. SNPs can alter the gene expression by affecting 
promoter activity and alter the protein product by affecting RNA splicing 
and the amino acid composition [18]. These alterations may lead to 
different metabolism and different responsiveness to drugs and 
carcinogens. SNPs can also result in inter-individual responses when 
these mutations are present in cell cycle regulatory genes, DNA repair 
genes, inflammatory genes etc [19].  
1.5 Carcinogenesis  
Carcinogenesis is the progression of a normal cell to a malignant cell. To 
become malignant the cell must overcome several check points and ignore 
regulatory signals for cell proliferation. In addition it must avoid 
apoptosis (programmed cell death) and any other programmed limitation 
to proliferation such as senescence and differentiation [20].  
In general carcinogenesis can be divided into 3 steps: initiation, promotion 
and progression. Initiation is when a hidden genetic alteration arises and 
is fixed in the genome by several rounds of cell division. This alteration 
may arise naturally, after exposure to a genotoxic chemical or after 
physical damage. The initiation step is irreversible. An initiated cell can 
be promoted by physical damage or by repeated exposure promoting 
substances. Promotion alters the genome expression of the initiated cell. 
It also enhances the proliferation signals and leads to excessive cell 
division. This gives rise to several benign pre-neoplastic lesions, but these 
will regress if the promoting agent is removed. Progression is the 
transition from a pre-neoplastic lesion to a malignant neoplastic lesion by 
major karyotypic alterations in the already genetically unstable cell. 
Progression is spontaneous and occurs with a low frequency [5,20,21].  
Cancer-critical genes are highly conserved and are categorized in two 
groups: proto-oncogenes and tumor suppressor genes. Mutations in proto-
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oncogene will lead to gain of function (oncogene) whereas in the tumor 
suppressor gene it will lead to loss of function. An oncogene can be 
identified as a gene that, when introduced into a normal cell, will result in 
cancer-like characteristics in the cell. In a normal cell the proto-oncogenes 
are transiently transcribed to regulate the cell cycle, but if they are 
permanently up-regulated they favor cell transition to a neoplastic lesion 
[5,20,22].  
1.6 Cell cycle control  
Cell division is necessary to replace dead and damaged cells in tissues and 
maintain epithelial turnover in for example the skin and the 
gastrointestinal tract. The immune system also uses this ability to mount 
an expanding adaptive immune response. If a damaged cell continues to 
divide and proliferate it may give rise to cancer. To help prevent this, the 
cell has a complex regulatory system to control the cell cycle [20,23,24].  
The cell cycle consists of two phases: the interphase and the mitotic phase 
(M phase). The interphase can further be divided into gap 1 (G1), DNA 
synthesis (S) and gap 2 (G2) phases which are shown in figure 1-3. 
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Figure 1-3: Overview of the cell cycle phases showing the involvement of 
different cyclin-dependent kinases and cyclins in addition to which 
cyclin-Cdk complexes initiate processes for entry into the next cell cycle 
phase. Modified after The Cell 4th edition [20]. 
G1, M and G2 provide cell cycle checkpoints and allow the cell to increase 
the amount of cytoplasm and number of organelles before continuing with 
either DNA synthesis or mitosis. The G1 checkpoint is dependent on 
environmental stimuli and if there is favorable conditions the S-phase is 
initiated. In late G2 the DNA must be fully replicated and the conditions 
favorable for the cell to enter M phase. Check point ensures that damaged 
/incomplete DNA does not become distributed to possible daughter cells 
[20,23].  
The cell cycle is mainly controlled by two groups of proteins; cyclins and 
cyclin-dependent kinases (Cdk). The cyclin-Cdk system is regulated both 
on gene level by regulating transcriptional activity and on protein level by 
phosphorylation, inhibitory proteins and proteasomal degradation [20,25]. 
It is often the G1 progression and the S phase initiation that are 
disrupted in cancer cells. The kinase activity during G1/S transition is 
mediated by a transcription factor called E2F. E2F binds to promoters in 
genes involved in S phase entry. E2F is controlled by the retinoblastoma 
protein (Rb) which is a cell cycle inhibitor. When the cell receives external 
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proliferation signals the amount of active cyclin-Cdk exceeds the amount 
of Rb and Rb is phosphorylated by the active Cdk. This reduces Rb’s 
affinity for E2F and it dissociates. E2F is then free to activate S-phase 
gene expression. Another important factor involved in the G1 checkpoint 
is the transcription factor and tumor suppressor gene product p53. 
Activation of p53 is often mediated through DNA damage and results in 
activation of DNA repair mechanisms, controlled cell death and/or cell 
cycle arrest [20,24,26]. 
Steroid hormones are involved in regulation of the cell cycle by 
modulating the effects of cyclin and Cdk inhibitory proteins. The effect of 
estrogens on proliferation is modulated by ERs. Estrogen-ER complexes 
functions as transcription factors or interacts with other transcription 
factors. Estrogens stimulate the G1 phase of the cell cycle by increasing 
the amount of G1 specific cyclins. This event is again regulated by Cdk 
inhibitors and activators [25].  
1.7 Apoptosis 
Apoptosis, or programmed cell death, is initiated in cells that are not 
longer needed i.e. during tissue formation, in damaged and in infected 
cells [27]. In contrast to necrosis, apoptosis does not affect the neighboring 
cells. An apoptotic cell will shrink and condense at the same time as the 
cell displays factors that cause it to be phagocytosed before any leakage of 
cell contents can occur. During necrosis cell content enters the extra 
cellular environment and induce inflammation [20]. Programmed cell 
death by apoptosis is characterized by the activation of a family of 
cysteine proteases called caspases. Caspases are tightly regulated by a 
number of factors such as Bcl-2, BAX and p53. Functional mutations in 
these will lead to dysregulation of apoptosis and possibly cancer [20,27].  
Examples of incidences that can induce the apoptotic program are 
disruption of the cytoskeleton, DNA damage, disruption of the 
endoplasmatic reticulum and ligand binding to death receptors (extrinsic 
pathway). All apoptotic pathways converge on one factor: cytochrome c 
(cyt c). Cyt c is found in the intermediate compartment in mitochondria. 
Released cyt c in the cytosol binds to the apoptosis activating factor 1 
(Apaf-1). This complex will activate caspase 9 which sequentially will 
activate caspases 3 and 7 leading to cleavage of downstream substrates. 
This mediates the breakdown of the cytoskeleton and nuclear envelope, 
condensation of DNA and signaling to phagocytic neighboring cells 
[20,23,27].  
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DNA damage frequently induces apoptosis, but the cellular response to 
the apoptosis signals varies with cell type, cell cycle status and 
differentiation state. The outcome is dependent on different expression 
patterns of pro- and anti-apoptotic factors [27].   
1.8 p53 - pathways and functions 
p53 is a tumor suppressor gene and its product is the transcription factor 
p53 which is involved in cell cycle control, apoptosis and maintenance of 
genetic stability. p53 is frequently mutated in cancers and the mutations 
usually lead to loss of p53 function [28,29]. In normal cells its activity is 
kept low to avoid cell cycle disruption and untimely death [29]. p53 is 
activated by factors disrupting its binding to the p53 inhibitor MDM2. In 
response to DNA damage p53 is phosphorylated by kinases. It can also be 
activated by a transcription factor called c-Myc which will induce the 
transcription of an MDM2 inhibitor called p14ARF. When p53 is activated 
it binds to several control regions for genes involved in maintenance of 
genetic stability, inhibition of the cell cycle and apoptosis [27,29]. p53 
induces or maintains growth arrest through expression of cell cycle 
regulators [30].  
Activation of the p53 pathway through DNA damage leads to several 
possible outcomes [31,32]. These outcomes are shown in figure 1-4.  
 
Figure 1-4: Effects of the p53 pathway showing different outcomes 
where the cell is able to repair/not repair the damage and subsequent 
tissue effects. Courtesy of Rodier et al [31]. 
When cells detect genotoxic stress they activate the DNA damage 
response. This response is a complex interaction between DNA repair 
factors and cell cycle regulators. Loss of p53 affects this response and 
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compromises proper DNA repair and cell fate decisions. The different 
types of DNA damage (base damage, adducts or strand breaks) recruit 
factors such as ataxia teleangiectasia mutated (ATM) protein kinase 
which will phosphorylate p53. This reduces binding to MDM2 and leads to 
stable activation of p53. In the case of severe damage, p53 will translocate 
to mitochondria and induce apoptosis or induce transcription of death 
receptors. If less severe the DNA repair machinery will be activated [31].   
1.9 Murine Double Minute 2 (MDM2) 
The MDM2 protein, a p53 inhibitor, is involved in cell cycle control, 
regulation of p53 activity and functions as an E3 ubiquitin ligase. MDM2 
is a proto-oncogene that will promote tumorigenesis when over expressed 
or mutated [33]. 
The structure of the MDM2 gene is showed in figure 1-5.  
 
Figure 1-5: An overview of the MDM2 gene showing exons 1 – 12, start 
codons and p53 response elements. The two major splice variants are 
also shown as MDM2-A and MDM2-B. From Iwakuma et al [33]. 
The human MDM2 gene is 34 kb in size, consists of 12 exons and is 
located on chromosome 12q13-14. The gene has 2 promoters: P1, P2 and 
there are also reports indicating a third promoter (P3) in the third intron 
of MDM2. The first start codon after P3 is located at the 50th amino acid 
in the full-length MDM2 protein which means that this version will be 
truncated by 49 amino acids. This will give a protein without a p53 
binding domain [34]. P1 is likely to regulate the MDM2 levels in non-
stressed cells. P2, which is p53 and radiation responsive, is located to the 
first intron and it is likely to regulate MDM2 levels in stressed cells 
[33,35]. The two promoters P1 and P2 can give rise to two different mRNA 
(messenger ribonucleic acid) products. These mRNA products give rise to 
the full length p90 (start codon in exon 3) and the shorter protein p76 
(start codon in exon 4). p76 is missing a part of the p53 binding domain, 
which makes it unable to interact with p53. It can also act as a dominant 
negative inhibitor of p90. Since p90 is inhibited by p76 it cannot interact 
with p53 and p53 levels will rise [33,35,36]. The consequence of 
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transcription from either of P1 or P2 is still unknown since the start codon 
for the full length protein is located in exon 3. It is thought that the RNA 
(ribonucleic acid) translation of products from P1 is less efficient than 
translation of products from P2 [35]. 
Alternative splicing (different exon combinations) of MDM2 has been 
identified in different cancer types as well as in normal tissues. In figure 
1-6 some alternative splice variant proteins are shown.  
 
Figure 1-6: Examples of alternative splice variant proteins of MDM2 
where many of them have no/truncated p53 binding domains. The RING 
domain is largely conserved as well as the zinc fingers. There are more 
than 40 known splice variants of MDM2. From Bartel et al [37]. 
Of the more than 40 splice variants found, the majority lacks a complete 
p53 interaction domain. In vitro studies have confirmed that 4 of these are 
unable to interact with p53 at all. Splice variant proteins are usually 
expressed alongside the full length MDM2 and it has been shown that 
they can regulate each other as exemplified by p76 and p90 MDM2 
transcripts [37]. Splice variants have been detected in both normal lung 
tissue and NSCLC tissue. Significantly higher amounts of alternative 
MDM2 variants have been seen in smokers versus non-smokers and 
males show more splice variants than women [38]. Some splice variants 
are only found in one or a few tumor types and suggest an association 
with tumorigenesis and contribution to tumor characteristics [39].  
The MDM2 protein contains several domains that are important for its 
different functions. The protein and an overview of the different domains 
are shown in figure 1-7. 
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Figure 1-7: Protein overview of MDM2 showing the p53 binding domain, 
the localization signals, the RING-domain, the zinc finger and the acidic 
domain. From Iwakuma et al [33]. 
MDM2 has three localization motifs; a nucleolar (NoLS) and a nuclear 
(NLS) import signal in addition to a nuclear export signal (NES). It also 
has several interaction domains; a RING domain, an acidic domain, a zinc 
finger and a p53 domain. The p53 interaction domain enables MDM2 to 
interfere with p53 transcriptional activity even when MDM2 is not 
expressed. This is accomplished when p53 binds to the p53 
transactivation domain on MDM2. This sequesters p53 and leads to 
expression of MDM2 to further bind p53. All the different localization 
signals lead the shuffling of MDM2 between the cytosol, nucleus and the 
nucleolar space. The RING domain is essential for the ligase function of 
MDM2. The acidic domain is involved in the binding of p300/CBP, 
whereas the function of the zink finger domain is unknown [33].  
MDM2 activity is regulated and there is a balance between when MDM2 
ubiquitinates itself or ubiquitinates other proteins. This balance is 
controlled by posttranslational modifications on the MDM2 protein such 
as sumoylation (SUMO stands for small ubiquitin-like modifier) and 
phosphorylation. When MDM2 is sumoylated its E3 ligase activity is 
shifted towards p53. MDM2 sumoylation is stimulated by p14ARF. 
Phosphorylation of MDM2 will attenuate the degradation of p53 as well. 
It has been suggested that acetylation of certain lysine residues in MDM2 
also will decrease the E3 activity [41].  
1.9.1 MDM2 and cell cycle control 
MDM2 interacts with several growth inhibitory factors such as p53, Rb 
and p14Arf. p14ARF is an alternative reading frame (ARF) of the 
CDKN2A locus and a growth inhibitor [42,43].  Retinoblastoma protein 
(Rb) is a tumor suppressor with functions similar to p53 in cell cycle 
regulation and cell death. MDM2 regulates its activity by binding Rb and 
disturbing Rb mediated G1 arrest [42]. MDM2 also interferes with Rb 
ability to inhibit the E2F transcription factor and the cell cycle will 
progress through G1 [33]. The MDM2-Rb interaction impairs the 
formation of a complex with p53 thereby overcoming MDM2’s ability to 
inhibit p53 mediated apoptosis [42]. MDM2 also interacts with the 
transcription factor Sp1. Binding prevents Sp1 to bind to its specific DNA 
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sequences and thus block transcription. This interaction is challenged by 
the Rb protein which will reactivate Sp1 by replacing Sp1 in the MDM2-
Sp1 complex. Since Sp1 is a general transcription factor the outcome of 
prevented transcription activation remains unknown [33,44].   
In addition MDM2 has three growth inhibitory domains and is thus 
believed to be involved in cell cycle control. Over-expression of the MDM2 
full length version will lead to G1 cell cycle arrest in a normal diploid 
human cell. MDM2 also seem to harbor a tumorigenic domain in its amino 
terminal and can therefore become oncogenic in a cell that does not sense 
the MDM2 mediated cell cycle arrest. It is also possible that several of the 
MDM2 splice variants code for this tumorigenic protein without 
functionally growth inhibitory domains [45]. MDM2 is often over 
expressed in cancers possibly inhibiting the p53 apoptotic pathway and 
the DNA damage response. Over-expression of MDM2 has been associated 
with both poor and favorable prognosis [39,40]. 
1.9.2 MDM2 and E3 ligase function 
MDM2 functions as an E3 ubiquitin ligase as part of an E1, E2 and E3 
ubiquitination complex. The E1 enzyme binds ubiquitin, which is a 76 
amino acid long protein, and activates it with the use of adenosine 
triphosphate (ATP). The activated ubiquitin is transferred to E2 which is 
a conjugation enzyme. E2 transfers ubiquitin to MDM2 (E3) which will 
ligate it to the target, for example p53. This ubiquitin is covalently bonded 
to a lysine residue in the target. MDM2 can also ubiquitinate itself 
[20,33]. The RING motif in MDM2 is a common E3 ligase motif 
responsible for the ligase activity in many proteins [33]. p14ARF binds to 
the RING domain responsible for the E3 ligase function of MDM2 to 
regulate its activity [43]. 
A protein can be ubiquitinated in two ways; polyubiquitination on one 
lysine residue or monoubiquitination on several lysine residues, and these 
will have different outcomes. A polyubiquitinated lysine will function as a 
signal for proteasomal degradation and when MDM2 ubiquitinates itself 
this is what will happen [20,33]. [33]. p53 is monoubiquitinated by MDM2 
and this means that other factors are involved in MDM2 mediated p53 
proteasomal degradation. At least 3 different domains in MDM2 seem to 
be necessary for this function: the p53 interaction domain to locate p53, 
the RING domain and the p300/CBP domain to completely mark p53 for 
degradation (see figure 1-7) [40,43]. p14ARF is a growth suppressor and 
can interact with both p53 and MDM2. It is shown that binding of 
p14ARF to p53 inhibits ubiquitination by MDM2 and thus inhibits p53 
degradation. P300/CBP (CREB binding protein) prevents p14ARF from 
interacting with MDM2 [33,46],[40]. 
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The deubiquitination enzyme HAUSP (herpes virus-associated ubiquitin-
specific protease) is a direct antagonist of MDM2 activity by 
deubiquitinating p53 after stimulation by DNA damage. HAUSP thus 
protects p53 from MDM2 mediated degradation [43]. HAUSP can also 
deubiquitinate MDM2 and has been shown to be involved in apoptosis 
[47]. Cells without HAUSP have an unstable MDM2 which leads to 
elevated levels of p53 [48],[49]. 
1.9.3 MDM2 and the tumor suppressor p53 
MDM2 is a negative regulator of p53. MDM2 regulates p53 in several 
ways; i) MDM2 binds to the DNA binding site on p53 and prevents p53-
DNA interaction and subsequent transcription activation. ii) MDM2 
ubiquitinates p53 as a signal for proteasomal degradation. iii) MDM2 
functions as an export signal to the cytosol of the MDM2-p53 complex 
[29,33]. MDM2 is one of the genes regulated by p53 as a transcription 
factor, but since MDM2 is a negative regulator of p53 this gives rise to a 
negative feedback loop [33]. Phosphorylation of MDM2 and p53 reduces 
the affinity for the p53-MDM2 interaction and p53 is then free to activate 
the DNA damage response [43]. 
MDM2 contains several localization signals and the nuclear export signal 
in MDM2 is critical for p53 degradation which takes place in the cytosol 
[33,40]. Later this notion has been challenged by the findings that p53 is 
degraded both in the cytosol as well as in the nucleus. p53 has two NES 
and the monoubiquitination by MDM2 reveals these [43]. Human p14ARF 
sequesters MDM2 in the nucleolus and blocks export of p53 to the cytosol 
[42]. 
1.9.4 Other members of the MDM2 family  
MDM4, also called MDMX, is an MDM2 related protein. The proteins 
have the highest homology at the amino terminal where the p53 binding 
domain is located. Residues involved in p53 interaction are conserved in 
both proteins as well as the RING domain. In additional they share a zinc 
finger in the central region of the proteins [33,50,51].  
Some studies have shown that MDM4 interacts with MDM2 via the RING 
domain to stabilize MDM2 by preventing autoubiquitinylation [46]. It 
binds to p53 with the same requirements as MDM2 and they cooperate in 
the regulation of p53. MDM4 does not function as an E3 ligase and has no 
NLS or NES. In the absence of MDM4, MDM2 is relatively inefficient at 
degrading p53 due to its very short half-life. Following DNA damage 
MDM2 marks MDM4 for degradation and the amount of MDM4 declines. 
MDM4 appears to mask the transcriptional activation domain on p53 and 
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thus inhibits p53. It also prevents p53 degradation by MDM2 [50]. The 
MDM2-MDM4-p53 interaction is summarized in figure 1-8.  
 
Figure 1-8: How MDM2, MDM4 and p53 interact. A: In an unstressed 
cell, p53 is kept at low levels due to MDM2-mediated ubiquitinylation. 
p53 is also kept inactive due to MDM4-mediated transactivation domain 
(TAD) occlusion. B: After stress, MDM2 degrades itself and MDM4, this 
leads to the accumulation and activation of p53. C: As activated p53 
transactivates MDM2, the increasing amount of MDM2 degrades 
MDM4 more efficiently, enabling full p53 activation D: Following stress 
relief, the accumulated MDM2 targets p53 again and p53 levels 
decrease. In addition as MDM4 levels increase, p53 activity also 
decreases. Modified from Toledo et al [32]. 
1.9.5 MDM2 and estrogen 
Studies have shown that MDM2 expression increase when the cells are 
exposed to estrogen. This is most likely an effect of ERα mediated 
transcriptional activation of MDM2 when estrogen is present [52]. MDM2 
has been shown to interact with ERα and can ubiquitinate ERα for 
degradation. Duong et al has shown that MDM2 is involved in both 
ligand-dependent and independent decrease of ERα stability. The ligand-
dependent decrease is executed in a complex with p53. The ligand-
independent pathway is a result of MDM2 over-expression where the 
interaction with ERα becomes p53 independent [14].  
It has also been seen a correlation between increased MDM2 expression 
and ERα in breast cancer. Here MDM2 interacted with ERα resulting in 
increased transcription of estrogen responsive genes [15].  
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1.9.6 MDM2 and other interacting factors  
There are several more proteins interacting with MDM2 and these are 
briefly overviewed in table 1-1 [33,41,43].  
Table 1-1: Factors interacting with MDM2.. 
 
1.10 Polymorphisms in MDM2 
There are at least 253 SNPs located in MDM2 reported to the NCBI 
(National Center for Biotechnology Information) SNP database where the 
majority of these are in introns [53].  
1.10.1 SNP309 
SNP309 was reported in a study by Bond et al where they investigated 
the possibility of naturally occurring genetic variations in important 
components of the p53 pathway. SNP309 is localized at position 309 in the 
MDM2 intronic promoter P2. This region is used by p53 to activate 
transcription of MDM2 [54]. An overview of the P2 region with SNP309, 
transcription factor binding sites and response elements is shown in 
figure 1-9.   
Introduction 
32 
 
 
Figure 1-9: SNP309 localization in intron 1. Binding sites for 
transcription factors Ets and AP1 are shown with p53 response 
elements. From Bond et al [54]. 
SNP309 is a T → G transversion and in the NCBI  SNP database it has 
the ID rs2279744 (sequence shown in appendix I). Bond et al also found 
that cells homozygous for SNP309 had a higher endogenous level of 
MDM2, and that there was a putative transcription factor binding site for 
Sp1 in the SNP309 region. They observed that the putative Sp1 binding 
site was extended by one nucleotide when the G allele was present. The in 
vitro elevated G/G promoter activity suggested that Sp1 can activate 
MDM2 transcription. This was verified by electro mobility shift assay 
(EMSA) with the G probe having higher affinity for purified recombinant 
human Sp1. Similar results obtained with nuclear cell extract. The MDM2 
promoter – Sp1 interaction was verified with the chromatin 
immunoprecipitation assay (ChiP) [36,54]. The elevated MDM2 levels 
were further shown to calm the p53 DNA damage response after exposure 
to the chemotherapeutic drug Etopside in that a lower death-rate in the 
cell cultures were observed [36,54].  
The increased in MDM2 transcription can be partly mediated by ER 
binding to the MDM2 P2 promoter. This in addition to the extended Sp1 
transcription site with the SNP309 G/G genotype may indicate that 
estrogen can influence the SNP309 effect on MDM2 transcription [52]. 
Bond et al proposed a possible chain of events shown in figure 1-10. 
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Figure 1-10: The model proposed by Bond et al for how the interaction 
between SNP309/gender/hormones and stress affects MDM2, p53 and 
tumor formation. In the presence of an active estrogen signaling 
pathway the G allele is thought to increase the MDM2 levels with the 
help of the extended Sp1 binding site. This will then attenuate the p53 
apoptotic pathway. From Bond et al [52].   
Further, ERα with estrogen present has been shown to be a potent 
activator of Sp1-driven transcription [55].   
SNP309 has later been both associated and not associated with several 
cancer forms, among others lung cancer, prostate cancer, colon cancer and 
endometrial cancer. A general overview of articles and their results are 
presented in appendix V. An overview can also be found in an article by 
Wilkening et al [56] where a combined analysis of the case-control studies 
available is described. A total of 4276 lung cancer cases and 5318 controls, 
from different ethnic populations, were analyzed and the results are 
shown in figure 1-11. 
Introduction 
34 
 
 
Figure 1-11: The combined analysis of lung cancer risk and SNP309 by 
Wilkening et al. The individual articles included in this analysis are 
shown on the left whereas the population studied is shown on the right. 
From Wilkening et al [56] 
For lung cancer an association with SNP309 was found, but the individual 
studies show some variability in their results.  The genotype distribution 
in different ethnic groups varies and this can be the reason that some 
population does not give rise to risk association where others do [56].  
1.10.2 C1797G 
A second functional SNP in MDM2 was recently reported by Wang et al 
[53]. This SNP is a C → G transition located in the P1 promoter of MDM2. 
In the NCBI SNP database it is given the ID rs937282 (sequence shown in 
appendix I) and is located ~780 bp upstream of SNP309.  
The genotype distribution varies in the different populations as shown in 
table 1-2.   
Table 1-2: Genotype distribution in different populations for SNP 
C1797G. From the NCBI SNP database. 
 
An association between the SNP and risk for bladder cancer was also 
reported [53]. Odds ratio (OR) for G/G homozygous genotype adjusted for 
age, sex, smoking and alcohol from a logistic regression model was 2,45 
(95 % CI 1,02-5,72). The authors also saw that the G/G genotype increased 
a putative binding site for the transcription factor C/EBPα and increased 
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the in vitro expression of MDM2. The C/EBPα binding was confirmed by 
EMSA. In 22 bladder tumor samples from Chinese individuals with 
different genotypes, carriers of the G/G genotype had higher MDM2 
mRNA levels as well as protein levels [53].  
1.11 Project aims and hypothesis 
Even though lung cancer is mainly correlated with exposure to cigarette 
smoke and other carcinogens, many studies indicate the involvement of 
genetic polymorphisms. Several polymorphisms in the MDM2/p53 
pathway have been identified and many of these have been associated 
with risk of lung cancer. Lind et al showed that SNP309 G/G was 
associated with NSCLC in a Norwegian population. The G/G genotype 
was associated with higher risk (OR 1,62) and in women this risk was 3 
times as high (OR 4,1). The higher risk in women may indicate 
involvement of sex-specific hormones [57]. Estrogens have the ability to 
induce maturation and differentiation of the ling at the same time that 
elevated estrogen levels is a known risk factor for lung cancer [58]. In 
addition there has been observed earlier age of onset in women with 
SNP309. The increased risk has been related to a higher transcriptional 
activity of MDM2 having the SNP309 G/G genotype [54,59]. It has been 
shown that SNP309 has an extended Sp1 binding site [54].  
The aim of this study was to characterize the promoter activity with the 
different genotypes and to see if these are consistent with the case-control 
study done by Lind et al. In addition this SNP was thought to be estrogen 
responsive and a higher transcriptional activity under estrogen exposure 
was expected.  
To investigate this two SNP309 reporter constructs were made. These 
contained approximately 500 bp of the P2 promoter, with SNP309 T/T or 
G/G genotypes, upstream of the reporter gene Firefly luciferase in the 
pGL3 basic reporter vector. These were transiently transfect them into 
human lung cell lines to characterize basal transcriptional activity. Since 
MDM2 is thought to be estrogen responsive transfected cells were also 
exposed to 17β-estradiol to characterize SNP309 estrogen responsiveness. 
Recently a new SNP called C1797G was found in the P1 promoter of 
MDM2 [53]. This SNP was found to affect MDM2 expression and it was 
associated with risk of bladder cancer in a Chinese population. To 
elucidate if there was any risk with C1797G and NSCLC in the 
Norwegian population, a series of lung cancer patients and matched 
healthy controls were genotyped and a risk association study was 
performed.  
Introduction 
36 
 
The work performed in this project is shown in figure 1-11. 
 
Figure 1-12: Overview of the work done in this project. 
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2. Methods 
2.1 Synthesis of MDM2 SNP309-T/G-Luc constructs 
The basis for the SNP309 construct synthesis is 6 DNA samples from the 
Biobank (Appendix IV) with known genotype for SNP309. The samples 
used in the construct synthesis originated from lung cancer patients and 
the DNA was isolated from the surrounding normal lung tissue or whole 
blood samples.  
2.1.1 Polymerase Chain Reaction (PCR) 
The polymerase chain reaction (PCR) is an in vitro method used to 
amplify specific DNA sequences. The reaction can be divided into three 
steps: denaturation, annealing and polymerization. These steps are 
illustrated in figure 2-1. 
 
Figure 2-1: The three steps in PCR. 
1. The denaturation step is usually done at 95 °C and removes 
undesired structures such as double stranded DNA (dsDNA) and 
DNA-primer complexes by disturbing the non-covalent interactions 
between the two strands. 
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2. Hybridization, also called annealing, is when the primer binds its 
complementary sequence in the template. The optimal temperature 
for this reaction is dependent on primer length and GC-content.  
3. During the polymerization (elongation) step the DNA polymerase 
elongates the primer to produce the complementary DNA strand 
(cDNA).  
Optimal conditions must be established for each reaction. A general 
reaction mixture would consist of: a forward and a reverse primer, 2’-
deoxy 5’-triphosphates (dNTPs), a heat-stable polymerase, reaction buffer, 
divalent cations and a DNA template. Steps one through three makes up 
one cycle and is repeated between 25 to 35 times. The reaction will 
terminate if one or more of the components become depleted.  
DNA samples, which were known to have either the SNP309 G/G or T/T 
genotype, were chosen and are shown in table 2-1. 
Table 2-1: DB samples used in PCR. 
 
A primer pair was designed to amplify a sequence of 471 bp containing 
SNP309. The fragment produced would function as a promoter when 
inserted upstream of the Firefly luciferase in the pGL3 basic luciferase 
vector. To facilitate the ligation into pGL3 basic the primers were 
designed to contain two different restriction sites (MluI and BglII) 
compatible with the multiple cloning region in pGL3 basic. The designed 
primers with added restriction sites (in bold) are shown in figure 2-2.  
 
Figure 2-2: Primers specific for the P2 region containing additional 
restriction sites that were incorporated in the final PCR product (shown 
in bold). 
The PCR reaction was set up in a total volume of 20 μl (shown in table 2-
2) and the PCR program is shown in table 2-3.  
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Table 2-2: Reaction mixture for the PCR. 
 
Table 2-3: PCR program. 
 
2.1.2 Agarose gel electrophoresis 
Agarose gel electrophoresis is a common technique used to separate, 
identify and/or purify DNA fragments according to size. Agarose is a 
linear polymer that is composed of alternating D- and L-galactose 
residues linked by glycosidic bonds. When the gel is placed under an 
electric field it is able to separate DNA from 50 bp (base pair) to several 
mega bases in size depending on the agarose concentration. The separated 
DNA is visualized by staining with fluorescent intercalating dyes, such as 
ethidium bromide (EtBr), which fluoresce when exposed to UV-light. PCR-
samples are mixed with a loading buffer which function is to visualize 
how far the gel has run (predictable rate). It also contains glycerol that 
weighs down the samples so that they collect in the bottom of the well.  
1. To make a small 2 % gel 50 ml of 1 x TAE buffer or 0,5 x TBE buffer 
was mixed with 1 g of SeaKem agarose and boiled in a microwave 
oven to completely melt the agarose (approximately 2 minutes).  
2. The agarose was cooled to about 50 C before adding EtBr to a 
concentration of 0,2 µg/ml (at higher temperatures the EtBr will 
break down) and the agarose was left to polymerize for 20 minutes. 
3. 5 μl of the PCR-sample was mixed with 2 µl of loading buffer and 
loaded on to the gel. A suitable DNA standard was loaded in a 
separate lane as a size reference.  
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4. The gel was run for 45 minutes at 100 V.  
2.1.3 Vectors 
pGL3 basic is a reporter vector containing the Firefly luciferase and the 
luciferase gene is cloned from Photinus pyralis (the firefly). It has no 
eukaryotic promoter or enhancer sequence and transcription from the 
Firefly luciferase is dependent on an insert in the multiple cloning site. 
One can also insert other possibly regulatory sequences in the enhancer 
region upstream of the multiple cloning site.  
pGL3 control is a reporter vector containing the SV40 promoter and 
enhancer sequences to ensure a high stable expression of Firefly 
luciferase. In this thesis this has been used as a transfection control.  
pRL-TK is an internal control vector containing the Renilla luciferase 
cloned from Renilla reniformis (the sea pansy). This gene is controlled by 
the herpes simplex virus thymidine kinase promoter which gives low to 
moderate levels of Renilla luciferase. This works as a baseline comparison 
and gives more stable results when co-transfected with Firefly luciferase 
vectors. 
All vector luciferase vector products are dependent on a substrate to 
generate luminescence since luciferases are enzymes. The substrates are 
given through buffers during the experiment (see chapter 2.3.5).  
All vector maps are shown in appendix II. 
2.1.4 Restriction digestion 
Restriction enzymes are a group of proteins derived from bacteria that 
have recognition sequences in DNA, usually palindromic 4-8 bp long 
sequences, to which they bind and cut. Restriction digestion can be used 
for genotyping and as a part of cloning.  
To construct the luciferase expression vector containing the MDM2 
promoter (SNP309-T/G-Luc constructs), the PCR product and pGL3 basic 
were digested with MluI and BglII restriction enzymes (double digest) to 
make sticky overhangs. This ensures insertion in the correction 
orientation in the subsequent ligation reaction. The double digest setup is 
shown in table 2-4. 
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Table 2-4: Restriction digestion of PCR product and vector. 
 
Both reactions were incubated for 2 hours at 37 C, separated on a 2 % 
agarose gel to confirm that the digestion products sizes.  
2.1.5 Purification of restriction digestion products 
To remove any unused components from the digestion mixture that might 
interfere with downstream reactions, the products were cleaned up using 
the QIAquick nucleotide removal kit.  
http://www1.qiagen.com/Products/DnaCleanup/GelPcrSiCleanupSystems/
QIAquickNucleotideRemovalKit.aspx 
This method is based on the use of resin columns that will bind DNA so 
that other residues can be washed away. After washing, DNA was eluted 
from the column in 150 μl of elution buffer. The purified products were 
further up-concentrated using Microcon® YM-30 Centrifugal Filter Units 
from Millipore.  
http://www.millipore.com/catalogue/item/42422 
This filter retained any DNA fragments larger than 50 bp dsDNA or 60 bp 
single stranded DNA (ssDNA) and the samples were finally eluted in 30 µl 
dH2O.    
2.1.6 Ligation of MDM2 insert and pGL3 vector 
A ligation reaction will glue together two pieces of DNA. This is done by 
an enzyme called DNA ligase which synthesizes phosphodiester bonds. 
The DNA ends either have complementary sequence overhangs or blunt 
ends, which will give either a specific or unspecific ligation, respectively. 
The enzyme used here is the T4 DNA ligase derived from the T4 
bacteriophage. It will join two cohesive DNA ends that have the 3’ 
hydroxyl termini and 5’ phosphate termini respectively. The ligation 
reaction setup is shown in table 2-5. 
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Table 2-5: Ligation reaction. 
 
The ligation reaction was run over night for 12 hours at 16 C followed by 
4 hours at 10 C. 
2.2 Work with Eschericia coli (E.coli).  
All work with bacteria was performed in a laminator air-flow bench (LAF) 
and basic sterile techniques were followed. All equipment, media and 
solutions were autoclaved or sterile filtered before use. The Escherichia 
coli (E.coli) strain used was 5-alpha F’Iq Competent E.coli (New England 
Biolabs).This strain has high transformation efficiency for non-methylated 
DNA derived from in vitro synthesis.  
2.2.1 Uptake of E.coli from long term storage 
1. A glycerol stock of the desired E.coli clone was taken from the -80 °C 
freezer and put on ice.  
2. A sterile inoculation pin was used to transfer a small amount of 
stock to 5 ml of LB-media in a Falcon tube.  
3. The culture was grown over night at 37 °C and 250 rpm. The next 
day the culture was ready for use.  
2.2.2 Long term storage of E.coli 
Storage of E.coli was done by freezing them to –80 C in LB-media 
containing 15 % glycerol. The glycerol content prevented lysis of the 
bacterial cell wall during freezing.  
1. Colonies were grown in 5 ml of LB-media to early lag-phase. 
2. 750 l of the culture was mixed with 250 l of 60 % glycerol and 
immediately put in liquid nitrogen.  
The glycerol stocks were stored at –80 C. 
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2.2.3 Transformation of E.coli and cloning of SNP309-T/G-Luc 
constructs 
Transformation is the uptake of foreign DNA from the external 
environment into bacteria. This process will take place if the bacteria are 
competent (able to take up DNA), either by induced mechanical stress 
such as electroporation or chemically induced with for example calcium 
dichloride (CaCl2) treatment. Bacteria can also be naturally competent, 
which is a genetic trait. DNA binding proteins on the bacterial surface 
binds the DNA and transports it through the cell wall. The foreign DNA 
can either be incorporated into the genome or it can reside in the 
cytoplasm and replicate independently of the bacterial genome. When a 
plasmid is taken up by a bacterium and replicated to make several copies 
we refer to this as cloning.  
The transformation was performed as follows:  
1. 2 μl of the ligation product (from table 2-6) was added to 50 μl of 
competent E.coli cells.  
2. The mixture was incubated on ice for 30 minutes, followed by a 
heat-shock for 30 seconds at 42 C and left on ice for 5 minutes.  
3. 950 μl of SOC medium (see appendix I) was added and the bacteria 
was incubated for 1 hour at 37 C and 250 rpm.  
4. The transformation mixture was plated out on Luria-Bertani (LB) 
and LB-Ampicillin agar plates (LB-amp) (see appendix I) with the 
dilutions 1:10, 1:20 and the remaining transformation mix on a last 
plate. The plates were incubated over night at 37 C.  
The following day Ampicillin resistant colonies (due to pGL3 beta-
lactamase gene) were picked and screened by PCR. For this PCR (table 2-
6), primers that bind in the vector sequence just outside the multiple 
cloning region, were used. These primers were RV3 and GL2 (see 
appendix II). 
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Table 2-6: PCR reaction for screening of colonies. 
 
The fragment size produced was expected to be 619 bp long.  
2.2.4 Plasmid isolation 
The positive colonies were picked and the plasmid isolated using the Mini- 
or Maxiprep using kits from Qiagen.  
Miniprep and Maxiprep 
These methods are based on the alkaline lysis of bacterial cells with 
sodium hydroxide (NaOH) followed by adsorption of the plasmid DNA on 
a silica gel in the presence of salt. After adding the NaOH the lysate is 
neutralized and SDS (sodium dodecyl sulphate) precipitates the 
chromosomal DNA and cell debris. The chromosomal DNA attaches to 
SDS, but the plasmid DNA renaturates and stays in suspension. The 
precipitate is removed by centrifugation and the supernatant is applied to 
the silica membrane. The silica membrane retains the plasmid DNA 
during all wash steps until elution. For protocols see URL below.  
http://www1.qiagen.com/Products/Plasmid/QIAprepMiniprepSystem/QIAp
repSpinMiniprepKit.aspx 
The output yield for Miniprep is estimated to be between 5 and 15 μg and 
for Maxiprep 20 µg to 500 µg. All isolated plasmids were checked with 
PCR containing GL2 and RV3 primers and restriction digestion with MluI 
and BglII enzymes as described in chapter 2.1.4.  
2.2.5 Sequencing 
There are two well-known and used methods for sequencing: the Sanger 
method and the Maxam-Gilbert method. The Sanger method is used in 
this thesis and is based on the generation of fragments that terminate at 
specific points along the sequence. Termination is the result of added 
dideoxy 5’-triphosphates (ddNTPs) in the sequencing mixture. The DNA 
template is mixed with a DNA polymerase, one sequencing primer, buffer 
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and both dNTPs (2’-deoxy 5’-triphosphate) and ddNTPs. The ddNTPs are 
labeled with non-radioactive fluorescent dyes and are incorporated 
randomly in the sequence. They will terminate the elongation because 
they lack the 3’ hydroxyl groups that would otherwise be a part of a 
phosphodiester bond. At the end of the reaction one will have fragments 
differing one nucleotide in size because of this random termination. The 
reaction mix is then run through a capillary which contains a polymer. A 
laser detects the ddNTPs signals and generates the sequence with the 
help of compatible software. 
The kit used was BigDye® Terminator v1.1 Cycle Sequencing Kit from 
Applied Biosystems. The kit contained a ready reaction mix with ddNTPs, 
dNTPs, buffer and polymerase as well as a positive control DNA. The 
sequencing was preformed with Applied Biosystems ABI Prism® 310 
Genetic Analyzer. The preceding single primer PCR reaction (table 2-7) 
was set up according to the enclosed protocol. 
Table 2-7: Single primer PCR reaction also containing ddNTPs. 
 
The reaction was run on a thermal cycler with the program shown in table 
2-8. 
Table 2-8: Single primer PCR program. 
 
The reaction products were cleaned up with DyeEx 2.0 Spin kit from 
Qiagen to remove any unincorporated ddNTPs that would otherwise lead 
false positive detection of non-existent bases. The kit is based on a resin 
gel, through which the DNA is filtered. The resin columns were vortexed 
to evenly disperse the resin before use and excessive fluid was removed by 
centrifugation at 2800 rpm for 3 minutes. The single primer PCR sample 
was added, spun down at the same speed/time and collected in an 
Eppendorf tube.  
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http://www1.qiagen.com/Products/DnaCleanup/DyeExDye-
TerminatorRemovalSystem/DyeEx2_0SpinKit.aspx 
The sample was freeze-dried and resolved in HiDi formamide in a total 
volume of 20 μl, before being mounted on the 310 Genetic Analyzer. 
Instruments were operated according to the manual with the use of POP-
6™ Polymer and running buffer, both from Applied Biosystems.  Colonies 
with the correct plasmid insert sequence were cultured and the plasmid 
was isolated with the Maxiprep kit (described earlier in chapter 2.2.4). 
2.2.6 Quantification of DNA 
The isolated SNP309-T/G-Luc constructs were quantified by using both a 
spectrophotometer (Eppendorf BioPhotometer) or by using Invitrogen’s 
Quant-iT™ PicoGreen® dsDNA Reagent. 
http://probes.invitrogen.com/media/pis/mp07581.pdf 
PicoGreen is a fluorophore that upon binding to dsDNA fluoresce. This 
nucleic acid stain is used to quantify the amount of dsDNA in a solution 
without being disturbed by any RNA or free nucleotides in the sample. 
The samples are mixed with the PicoGreen reagent and analyzed on a 
spectrofluorometer. Concentrations are calculated based on the standard 
curve made from the enclosed Lambda DNA and are shown in table 2-9.  
Table 2-9: PicoGreen standard curve dilution series. 
 
The standard and the samples were read using a Packard Fusion 
microplate analyzer.  
The results from the standard dilution series were plotted and linear 
regression was done to the standard curve. By the use of linear regression 
the standard curve function was obtained. Sample concentrations were 
found by reading of the standard curve and calculation backwards by 
considering the dilutions. An example of a PicoGreen standard curve is 
shown in figure 2-3. 
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Figure 2-3: PicoGreen standard curve showing both the curve function 
and the R2 value. 
The sample concentration was found by reading of the standard curve 
from the sample luminescence value and calculation backwards 
considering the dilutions. 
2.3 Human cell culture experiments 
All techniques involving cell cultures were performed in a LAF bench and 
basic sterile techniques were followed. All equipment, media and solutions 
were autoclaved or sterile filtered before use. The cells used were both 
human cancerous and immortalized cells (see appendix I). 
2.3.1 Thawing of cells from liquid nitrogen storage 
During uptake of a desired cell line from liquid nitrogen storage the 
following protocol was followed: 
1. A vial containing the desired cell line was taken out of liquid 
nitrogen storage and put on ice.  
2. The vial was transferred to a beaker of 70 % ethanol pre-warmed to 
37 C.  
3. The cell culture was thawed about ¾, transferred to a 15 ml Falcon 
tube where 5 ml of appropriate media was added slowly (about 2 
minutes).  
4. The suspension was spun down for 4 minutes at 1000 rpm and the 
supernatant was discarded to remove all DMSO (dimethyl 
sulphoxide).  
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5. Cells where resuspended in 8 ml of complete media and transferred 
to a 9 mm Petri dish or a 15 cm2 flask. Cell culture media was 
changed the next day.  
2.3.2 Maintaining epithelial and suspension cell cultures 
After reaching confluency the cells were replated with the use of a trypsin 
solution (PET). Trypsin degrades the cell adhesion molecules anchored to 
the plastic dish allowing us to replate the cells and maintaining the cell 
culture. The technique is done as follows: 
1. Cells were washed with 3-5 ml of phosphate buffered saline (PBS).  
2. 1 ml of PET containing 0,02 % trypsin was added and the petri dish 
was placed in the incubator until the cells were in suspension.  
3. The trypsination was stopped by adding 3 ml of complete media 
containing serum.  
4. Cells in suspension were transferred a Falcon tube and spun down 
for 4 minutes at 4 °C and 1000 rpm.  
5. The supernatant was discarded and the cells were resuspended in 3-
5 ml of media. If the cells were to be used in an experiment they 
were counted by using a Bürker counting chamber and distributed 
to appropriate dishes/flasks in known numbers. If they were not to 
be used in an experiment they were distributed 1:4 to 1:10 
depending on the cell line.  
When working with suspension cells the culture was spun down directly. 
When used in an experiment the cells were stained with Trypan blue 0,4 
% (50µl cell culture in 450 µl Trypan blue) before counting. Trypan blue is 
used to distinguish between viable and dead cells where dead cells became 
blue because of permeated cell membranes.  
2.3.3 Storage of human cells in liquid nitrogen  
Human cell lines are stored in liquid nitrogen suspended in a DMSO 
(dimethyl sulphoxide)/antibiotic/media solution where the DMSO prevents 
crystallization and lysis of cell membranes. To freeze the cells the 
following was done: 
1. When the cells were grown to confluency they were trypsinated 
according to protocol 2.3.2, spun down and resuspended in antibiotic 
freeze media (AF, 500 l per vial to be used).  
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2. The cells were distributed to vials and 500 l of DMSO 8% was 
added to each vial.  
The freezing process was done gradually to –80 C before being stored in 
the liquid nitrogen tank.  
2.3.4 Transient transfection 
Transfection is the delivery of cloned DNA into a eukaryotic cell and can 
be achieved by three means; biochemical transfection, physical 
transfection and virus-mediated transduction. The choice of method is 
based on the cells ability to survive the stress that comes with chosen 
transfection protocol and efficiency requirements. Transfection can be 
divided into two groups; stable and transient transfection. Stable 
transfection is used to make a clonal cell line where the transfected 
DNA/gene is integrate into the chromosomal DNA. Here, if it is a gene, it 
will be transcribed and produce moderate amounts of protein. The DNA 
integrated into the genome needs to contain a selection marker (for 
example antibiotic resistance) so that transfected clones can be selected 
from the non-transfected cells. The efficiency of stable transfection is 1-2 
orders of magnitude lower than for transient transfection. During 
transient transfection the recombinant DNA is introduced into cells, but 
temporarily. This gives a high level of expression of the target gene, but 
the DNA is not necessarily incorporated into the chromosomal DNA. 
Other functions, such as promoter activity, can also be analyzed. 
Transient transfection is a desired method when working with many 
samples and results are obtained within fairly short time.  
In this thesis a transient biochemical transfection is used. A cationic lipid 
solution is mixed with the negatively charged DNA to form DNA-lipid 
vesicles (liposomes). These liposomes, where the lipids are positively 
charged, fuse with the negatively charged cell membrane to transfer DNA 
across the lipid bilayer.  
Three different transfection reagents were used during optimalization of 
the transfection. In the end the preferred reagent was NEB TransPass™ 
D1. For all transfection reagents each replicate contained 200 000 cells 
(all except for BEP-2D and BEAS-2B which had 250 000 cells) which were 
distributed to one 3,5 cm dish. Each individual experiment consisted of 
three replicates per condition/parameter and the following day the cells 
were approximately 50-80 % confluent. In every experiment a positive 
control and negative control was included. The positive control was the 
pGL3 control vector containing the SV40 promoter and enhancers to give 
a strong positive control signal. The negative control was a transfection 
without DNA.  
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Set 1 – Lipofectamin and Plus reagents (optimalization only). 
. Transient transfection was carried out as follows: 
1. To 100 µl of transfection media 1 µg of the SNP309-T/T-Luc or 
SNP309-G/G-Luc construct and 0,1 µg of Renilla vector was added 
and mixed. 
2. 4 µl of Plus reagent was added and after mixing the reaction was 
incubated for 15 minutes at room temperature. 
3. To 100 µl of new transfection media 5 µl of Lipofectamin was added. 
The solution was mixed and added to the DNA/Plus reagent 
solution. Incubated for 15 minutes at room temperature. 
4. The Lipofectamin-DNA-Plus reagent mix (200 µl) was diluted in 1 
ml of transfection media and distributed to the petri dish. The cells 
were incubated for 3 hours at 37 °C. 
5. After incubation the cells were washed with 1 ml of PBS before 
adding 2 ml of complete media. 
Set 2 – FuGENE 6 transfection reagent (optimalization only).  
1. To 100 µl of serum free media 3 µl of FuGENE reagent was added.  
2. After mixing, 1 µg of the SNP309-T/T-Luc or SNP309-G/G-Luc 
construct and 0,1 µg of Renilla vector was added. The solution was 
mixed and incubated for 15 minutes at room temperature.  
3. The transfection mixture was added directly to the complete media 
in the dish and the cells were incubated over night at 37 °C.  
4. The following day the cells were washed with 1 ml of PBS and 
complete media was added. 
Set 3 – NEB TransPass™ D1.  
1. To 1 ml of serum free media 3 µl of transfection reagent was added.  
2. After mixing, DNA was added and the solution was incubated for 
20-30 minutes at room temperature. A total of 1,1 µg or 1,05 µg 
DNA was used, the latter for H2009 cells only, to give either a 1:10 
or 1:20 ratio.  
3. The cells were washed with 1 ml of PBS before adding the 
transfection mixture. and incubated for 3 hours at 37 °C.  
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4. After incubation the cells were again washed with PBS and 2 ml 
complete media was added. The cells were incubated for 
approximately 24 hours at 37 °C.  
2.3.5 Dual-Luciferase® Reporter assay system 
The pGL3 basic vector used in the synthesis of the SNP309-T/G-Luc 
constructs contains a Firefly luciferase gene downstream from the 
multiple cloning site. Introduction of the MDM2 promoter will therefore 
control the activity of this downstream reporter gene. The SNP309-T/G-
Luc constructs were transiently co-transfected with the Renilla luciferase 
vector. The two different luciferases are activated by different buffers 
containing specific substrates and thus the co-transfected Renilla vector 
will give a baseline for comparison to the Firefly luciferase activity. When 
using the ratio between the two luciferases one will achieve more stable 
results. Because the Firefly luciferase gene is regulated by the promoter 
insert, the ratio between the Firefly and the Renilla vector will give an 
indication of the MDM2 promoter activity compared with the different 
SNP309 genotypes. 
After the completed transient transfection the Luciferase/Renilla ratio 
was read with the use of Promega’s Dual-Luciferase® Reporter assay kit.  
1. 200 µl of 1 x Passive Lysis Buffer was added to the transfected cells 
and the dish was placed on a gyrotray for 15 – 30 minutes to achieve 
cell lysis and freeing the luciferase enzymes.  
2. To each well to be used on a 96 well plate 100 µl of Luciferase Assay 
Buffer II was added. This buffer will provide substrate the Firefly 
luciferase produced by the SNP309-T/G-Luc constructs.  
3. 20 µl of sample was added to each well before mixing. The 
luminescence from the Firefly was read for 1 second on the 
luminometer.  
4. To the same well 100 µl of Stop & Glo buffer was added before 
mixing. This buffer contains a substrate for the Renilla luciferase 
produced by the pRL-TK as well as a quencher for the Firefly 
luciferase activity. The luminescence from Renilla luciferase was 
read as for the Firefly luciferase. The ratio Firefly/Renilla 
luminescence was then calculated.  
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2.3.6 Exposure of cells to 17β-estradiol  
Transient transfected cells were also exposed to 17β-estradiol immediately 
after transfection. This was done with three concentrations of 17β-
estradiol (0 nM, 1nM and 10nM) with 3 replicates for each concentration.  
1. Cells were plated and transiently transfected as described in 
chapter 2.3.4 with NEB TransPass™ D1.  
2. In 2 ml of complete media, 17β-estradiol solved in DMSO was 
diluted to the concentration of 10 µM.  
3. For each dish to be exposed 2 ml of media was to be used and 17β-
estradiol from the 10 µM stock was diluted to 10 nM and 1 nM. 
DMSO content in the final cell culture media was never above 1 ‰. 
4. 17β-estradiol was added immediately after the 3 hours incubation 
step in transient transfection after washing with 3-5 ml of PBS.  
5. Incubated for 24 hours and the luciferase and renilla luminescence 
were read as described earlier with the DLR™ assay (chapter 2.3.5).  
2.4 Genotyping 
TaqMan is a PCR based method where there are specially designed 
primers and a SNP specific set of reporter probes (oligonucleotides) 
involved. The probes are labeled at the 5’ end with a fluorescent group 
(here FAM for G/G and VIC for C/C). At their 3’ end there is a non-
fluorescent quencher that will eliminate background noise and make the 
assay more sensitive. The quencher absorbs any fluorescence from the 
reporter group in an intact probe due to close proximity between the two. 
During the PCR there will be generated more sequence specific DNA that 
the probes will bind to, but when the DNA polymerase replicates the 
template its 5’-3’ exonuclease activity will cleave the fluorophore from the 
probe. The quencher can no longer absorb the fluorescence from the 
fluorophore and a signal can be detected. The signal intensity increase as 
the PCR progresses as a result of more probe cleavage. Since the two 
probes are specific for either one of the SNP genotypes, one or both 
fluorophores will dominate in a reaction giving either a homozygous or 
heterozygous genotype. Several SNPs can be genotyped in a single 
reaction as long as the probes have different fluorophores.  
TaqMan assays from Applied Biosystems have been improved by using a 
Minor Grove Binder. This contacts the DNA helix in the minor groove and 
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improves probe-template specificity and interaction stability. In figure 2-4 
an overview of the TaqMan PCR reaction from Applied Biosystems is 
shown.  
 
Figure 2-4: Overview of the TaqMan method. From Applied Biosystems. 
2.4.1 Restriction Fragment Length Polymorphism (RFLP) 
This is another genotyping method based on PCR and restriction 
digestion. It is dependent on that a site-specific restriction enzyme site is 
present in the SNP sequence and that it is disrupted when the other SNP 
genotype is present. The PCR primers are designed so that digestion 
fragments can be readily separated on an agarose gel. The PCR is run 
with the specific primers and run on an agarose gel to ensure the presence 
of a PCR product. The PCR product is then digested with the chosen 
enzyme. The restriction reaction is loaded onto a high concentration 
agarose gel and run.  
Both SNP309 and C1797G could be genotyped this way. Cell lines used in 
transient transfection with SNP309 constructs where genotyped to 
elucidate endogenous SNP309 status. Biobank samples for the C1797G - 
lung cancer association, that were not genotyped with TaqMan, were also 
genotyped this way.  
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SNP309 
A PCR was run as described in chapter 2.1.1. This PCR was the digested 
with MspA1I restriction enzyme. The SNP309 G allele gave rise to an 
additional restriction site for this enzyme. The restriction digestion was 
set up as described in table 2-10 and separated on a 4 % agarose gel with 
EtBr.  
Table 2-10: RFLP restriction digestion for SNP309. 
 
C1797G 
The primers designed for C1797G are shown in appendix II. This SNP 
gives rise to a site for the restriction enzyme Hpy188I. A PCR reaction 
was set up as shown in table 2-11 which was further digested with 
Hpy188I as shown in table 2-12 to be separated on a 4 % agarose gel with 
EtBr.   
Table 2-11: Preliminary PCR for subsequent RFLP genotyping of SNP 
C1797G. 
 
Table 2-12: RFLP restriction digestion for SNP C1797G. 
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2.4.2 TaqMan genotyping of biobank for SNP C1797G 
The TaqMan reaction was run on 384 well plates covered with optical 
film. In table 2-13 an overview of the reaction contents is shown. The 
TaqMan PCR program is shown in table 2-14. 
Table 2-13: TaqMan reaction contents. 
 
Table 2-14: TaqMan PCR program. 
 
1. The SNP assay mix was thawed on ice while the DNA samples were 
mixed and spun down.  
2. All components of the reaction, except DNA template, were mixed 
and distributed in every other row on the 384 well plate.  
3. DNA template was added and the plate was covered with optical 
film, spun down and placed on the thermal cycler.  
4. The plate was read and the data analyzed with the Applied 
Biosystems 7900 HT and supplementary SDS 2.0 software.  
2.5 Statistics 
A description of the statistical methods used in this thesis is described in 
this chapter. For a thorough description of the details behind the 
statistical methods please see appendix VI.  
One assumes that in vitro cell culture experiments gives normally 
distributed results, but before any statistical analysis was performed the 
data was checked for normally distribution with the use of SigmaPlot 
10.0. SigmaPlot uses the Kolmogrov-Smirnov test to see if the data 
provided is normally distributed. This test standardizes the data and 
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compares them to a standard normal distribution The normality test was 
passed before continuing with the selected T-test or ANOVA (analysis of 
variance) test.  
2.5.1 P-values and odds ratios (OR) 
P-values 
The p-value is a measurement of the probability of achieving a result that 
is alike or more extreme than what is observed. This value is based on 
true null hypothesis so one can also describe it as the amount of evidence 
you have against the null hypothesis. One rejects the null hypothesis if 
the p-value is less than the level set as significant (usually 0,05). If the 
null hypothesis is true, a p-value of 0,05 indicates that there is only a 5 % 
likeliness that the results you have are like those observed [60].  
Odds ratio 
Odds ratio can be defined as the ratio between the odds of a certain 
happening in one group and the odds for the same happening in another 
group. The groups must be dichotomous (from the same whole, but not 
overlap). An odds ratio of 1 indicates that the odds are the same in both 
groups. An odds ratio > 1 indicates that the event is more likely in the 
first groups as a ratio < 1 indicates more likeliness in the second group. 
The odds ratio must be ≥ 0 [60].  
2.5.2 Linear regression 
A regression analysis will study the relationship between 2 variables 
where one is dependent and the other is explanatory/independent. The 
relationship is assumed to be linear, the observations independent and 
that the errors have the same variability. Linear regression gives the 
regression line function as shown in equation 1. 
 
Here b describes how much the y-value will change with one unit 
difference in x.  
To find the regression line the method of least squares is employed. It 
calculates the smallest deviation from a straight line for all the data 
points present. 
Also the R2 value can be calculated and this is the Pearson’s coefficient of 
correlation. Pearson’s coefficient will be used with normally distributed 
data and will vary between -1 and 1 for negative and positive correlation, 
respectively. It describes the strength and direction of the linear 
Methods 
57 
 
relationship between the two variables and how much variation there is 
around the regression line. For an increasing regression line the value 
should be as close as possible to 1 because of the positive correlation. A 
value closer to 0 will indicate no linear relationship between the variables 
[60].  
2.5.3 T-test 
The T-test (Student T-test) is used to study the differences in means or 
medians in a group of observations. There are two types of this test: 
paired T-test and T-test. The T-test can be used to conclude on 
observations in one group or in two groups. Two groups of data can be 
analyzed as one (paired T-test) but the data must then be related and the 
difference between observations must be calculated. An example where 
the paired T-test can be used is when measuring the blood pressure in one 
patient before and after treatment. The T-test can be used when 
comparing the same parameter in two different groups.  
The paired T-test has been chosen in this thesis when comparing the 
activity of SNP309 G/G and T/T constructs transiently transfected into 
human cell lines. This choice is based on that the constructs are alike 
except for that one SNP, that the experiment conditions are otherwise the 
same and that a cell culture is derived from one larger culture and thus 
all cultures are assumed to be identical.  
2.5.4 ANOVA (Analysis of variance) 
ANOVA, which is a parametrical statistical test, is an alternative 
regression analysis where the dependent variable is continuous, like in 
regression analysis, and the explanatory variable is categorical. In these 
situations one can choose between regression analysis and ANOVA. 
ANOVA is used when there are more groups than 2 for comparison and 
the T-test cannot be used. The data needs to be normally distributed, 
independent and equal variance in the groups. The principle is to use the 
variance instead of standard deviation to analyze a sample group’s 
variability [60].  
2.5.5 Logistic regression analysis (SNP association study) 
In a case-control study the higher the number of samples the more 
statistical conclusions one can make based on the test results and they 
will be more accurate. The confidence interval calculated from the 
observations in the study will give a measure of the accuracy of the mean 
calculated. This interval will, with a certain degree of accuracy, show the 
lowest and highest value that the true population might have. In a risk-
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association one can study, for example, a genotype distribution in both 
healthy controls and disease cases, possibly identifying a risk allele. The 
control group is often matched to the case group to ensure that the two 
are as similar as possible. This is especially important in consideration of 
risk factors for the disease or other outcome investigated. Risk factors can 
be age, smoking habits, gender, diet etc [60].  
Logistic regression is a model where the probability of an incidence is 
found by plotting the data to a logistic curve. The variables may be either 
categorical or numerical. This test is often used when testing for 
associations between various genotypes and disease. The genotype 
distribution in controls should be in Hardy-Weinberg equilibrium. This 
equilibrium is based on that various genotypes in a randomly mating 
population will have a certain distribution. This is not so important for 
cases since we then are selection certain individuals from the population. 
When using logistic regression one can include correction for confounding 
factors such as age, smoking, gender etc to obtain a more accurate 
modulation of the possible risk that will accompany the factor one is 
analyzing [60]. 
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3. Results 
3.1 Construction of MDM2 SNP309-T/G-Luc expression 
vectors 
3.1.1 Cloning 
In order to insert the MDM2 P2 promoter, with a G or T at the SNP309 
position, into the reporter vector pGL3 basic, primers specific for the 
MDM2 P2 region were used. The forward primer contained a restriction 
site for the endonuclease MluI and the reverse primer contained a 
restriction site for BglII. DNA from 3 individuals, harboring either the 
G/G or T/T genotype, was used as template. The PCR product would have 
the expected size of 471 bp which was confirmed by agarose gel 
electrophoresis (figure 3-1). Ladders are shown in appendix I. 
 
Figure 3-1: MDM2 P2 PCR products of DNA samples shown with a 100 
bp ladder. Samples DB503, DB 499 and DB 501 contained the T/T 
SNP309 genotype. Samples DB507, DB495 and DB539 contained the 
G/G SNP309 genotype. All samples had the expected size of 
approximately 500 bp. 
Both the PCR products and the pGL3 basic vector were double digested 
with MluI/BglII and ligated together. The finished expression vector 
comprising of pGL3 basic and the inserted MDM2 P2 promoter region is 
shown in figure 3-2.  
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Figure 3-2: Vector map of the SNP309-T/G-Luc construct with the 
MDM2 P2 promoter inserted upstream for the luciferase gene 
(reporter). The forward primer RV3 and the reverse primer GL2 are 
marked.   
The SNP309-T/G-Luc expression vectors were transformed into competent 
E.coli. After transformation, AmpR (Ampicillin resistant) colonies were 
checked with a control PCR containing primers RV3 and GL2 which bind 
in the vector sequence. Primer locations are shown in figure 3-3. Colonies 
containing the expected 613 bp fragment were sequenced to verify 
SNP309 genotype and to ensure integrity of the DNA sequence. 
Sequencing results from an E.coli colony containing either SNP309-G/G-
Luc or SNP309-T/T-Luc, respectively, is shown in figure 3-3. 
Complementary nucleotides were detected since the forward primer was 
used and synthesizes the complementary strand. See appendix II for more 
details.  
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Figure 3-3: Sequencing results of SNP309-T/G-Luc constructs, G and T 
respectively. Reverse primer used and therefore complementary 
nucleotides are shown. 
Two colonies containing the correct SNP309-Luc construct for either G/G 
or T/T genotype were selected, amplified and the plasmids were isolated 
by Maxiprep. A new round of PCR and restriction digestion was 
performed to further verify the correct plasmid contents before use in cell 
culture experiments.  
3.2 Human cell culture experiments 
The SNP309 constructs were transiently co-transfected with pRL-TK 
(Renilla) into human lung epithelial cell lines and later also epithelial cell 
lines from cervix, breast and colon (shown in table 3-1 and 3-2).  
For each cell line at least three individual experiments were performed. In 
each of these experiments three replicates were used. The mean and 
standard error (SE) from the replicates was used in the paired t-test to 
test for differences transcriptional activity. The results are shown as 
means plotted with SE in histograms. Asterix (*) indicate statistical 
significance p < 0,05 with * and p < 0,01 with **. 
To elucidate if SNP309 was estrogen responsive four lung epithelial cell 
lines were exposed to 17β-estradiol after transient transfection. A 
comparison of unexposed (0 nM) and exposed cells (1 nM and 10 nM 17β-
estradiol) was performed with the ANOVA test.  
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All raw data from transient transfection are shown in appendix III.  
3.2.1 Transfection results from human lung cell lines 
The SNP309-T/G-Luc constructs were transiently transfected in both 
immortalized normal and cancerous human lung cell lines to study 
SNP309 effect on the MDM2 P2 promoter transcriptional activity in cell 
culture systems. The lung cell line details are shown in table 3-1. 
Table 3-1: Lung epithelial cell lines used in transient transfection. 
 
Cell lines were co-transfected with either SNP309-T/T-Luc or SNP309-
G/G-Luc together with pRL-TK. The relative transcriptional activity was 
calculated (Firefly/Renilla ratio) and a paired t-test was performed. In 
figure 3-4 A-E the results from all transfected human lung cell lines are 
shown.  
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Figure 3-4 A-E: Relative transcriptional activity from SNP309-T/T-Luc 
(green) and SNP309-G/G-Luc (red) vectors. Statistical analysis 
performed with the paired t-test. Error bars = SE. 
All lung cell lines, both immortalized and cancerous, showed increased 
transcriptional activity with the SNP309-T/T-Luc expression vector. NCI-
H2009, the only female lung cell line, showed inverted ratios with the 
Renilla activity being higher than the Firefly activity. A549 was the cell 
line showing the most transcription from the both vectors whereas the 
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immortalized cell lines BEAS-2B and BEP-2D had the lowest. The 
different cell lines had various ratios indicating diverse inter cell line 
luciferase construct transcription.  
To investigate if the higher transcriptional activity from SNP309-T/T-Luc 
was tissue specific, 3 additional cell lines originating from other tissues 
were transfected. These cell lines are listed in table 3-2.  
Table 3-2: Non-lung cell lines used in transient transfection. 
 
These cell lines were treated the same way as the lung cell lines from 
table 3-1. In figure 3-5 A-C the results from all transfected human lung 
cell lines are shown.  
 
Figure 3-5 A-C: Relative transcriptional activity from SNP309-T/T-Luc 
(green) and SNP309-G/G-Luc (red) vectors in cell lines originating from 
cervix, colon and breast. Statistical analysis performed with the paired 
t-test. Error bars = SE. 
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Also in these cell lines the result was increased transcriptional activity 
from the SNP309-T/T-Luc vector. MCF-7 was the cell line inducing the 
highest transcriptional activity from the SNP309-T/G-Luc constructs. 
HeLa (also a female cell line) showed inverted ratios with Renilla activity 
higher than Firefly activity for SNP309-G/G-Luc. Again the different cell 
lines had various ratios indicating diverse inter cell line luciferase 
construct transcription.  
3.2.2 Transient transfection with subsequent 17β-estradiol exposure 
There are reports that MDM2 is estrogen responsive (see chapter 
1.9.5).Therefore to characterize possible estrogen responsiveness for 
SNP309, transiently transfected cells were exposed to 17β-estradiol for 24 
hours. For these experiments the cell lines A549, NCI-H2009, BEAS-2B 
and BEP-2B, were chosen. Cell lines were co-transfected with SNP309-
T/T-Luc or SNP309-G/G-Luc with pRL-TK with following exposure to 17β-
estradiol (1 nM and 10 nM) for 24 hours. Relative transcriptional activity 
was calculated and exposed replicates were compared with an unexposed 
control. The results are presented in figure 3-6.   
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Figure 3-6 A-D: Relative transcriptional activity from SNP309-T/T-Luc 
and SNP309-G/G-Luc with increasing concentrations of 17β-estradiol. 
Statistical analysis performed with ANOVA. Error bars = SE.   
In figure 3-7 it is evident that the SNP309-T/T-Luc construct still has a 
higher transcriptional activity. In figure 3-7 A and B the A549 and NCI-
H2009 tumor cell lines show a slightly increased transcriptional activity 
for the T/T genotype with 10 nM of 17β-estradiol present. NCI-H2009, a 
female cell line, shows a trend towards decreased transcriptional activity 
with the G/G genotype with 10 nM 17β-estradiol present in contrast to 
A549. Both immortalized cell lines (figure 3-7 C and D) show no specific 
trend after 17β-estradiol exposure. For the cell line BEAS-2B exposed 
cultures have a higher ratio than non-exposed cultures. BEP-2D seems 
have the same transcriptional activity from both constructs. None of the 
results shown in figure 3-7 were statistical significant with the ANOVA 
test. In table 3-3 ER status and endogenous SNP309 genotype status is 
shown for the cell lines exposed to 17β-estradiol.   
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Table 3-3: Overview of ER status in cell lines exposed to 17β-estradiol. 
 
In tables 3-4 and 3-5 a summary of the cell culture experiments are shown 
with P-values and more transcriptionally active genotype.  
Table 3-4: Summary of transient transfection experiments. 
 
Table 3-5: Summary of 17β-estradiol exposure experiments. 
 
3.3 Verification of SNP genotypes 
Biobank samples were genotypes for both SNP309 and C1797G. 
Genotyping and SNP association studies with SNP309 was done before 
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this project was started [57]. To characterize the endogenous SNP309 
genotype status the all cell lines were genotyped as shown in chapter 
2.4.1.  
3.3.1 Genotyping of SNP309 with RFLP  
For SNP309, the cell lines used were genotyped with RFLP. When 
digesting the PCR fragment (from MDM2 specific primers) with MspA1I 
the T/T genotype would give 233 + 113 + 93 + 31 bp fragments and the 
G/G genotype 187 + 113 + 93 + 46 + 31 bp fragments, respectively. 
Samples with the T/G genotype would have 233 + 187 + 113 + 93 + 46 and 
31 bp fragments. In figure 3-7 an agarose gel picture of PCR products 
digested with MspA1I is shown with some of the samples genotyped.   
 
Figure 3-7: Genotyping of SNP309 with RFLP in cell lines. The two 
fragments 233 bp and 187 bp (indicated by arrows) distinguish the 
different genotypes.  
The endogenous SNP3009 genotype status in all cell lines is shown in 
table 3-6. 
Table 3-6: SNP309 genotype in cell lines. 
 
3.3.2 C1797G genotyping of lung cancer paitens and controls 
The Biobank contains DNA samples isolated from lung cancer patients as 
well as controls which has been isolated from blood or normal adjacent 
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lung tissue. The samples used here are matched on age, smoking and 
gender. Samples were genotyped for SNP C1797G located to the P1 
promoter in MDM2 with the TaqMan method. This assay consists of two 
probes specific for each allele of the SNP. The two probes are labeled with 
different reporter fluorophores (VIC and FAM) that can be distinguished 
in solution.  The TaqMan instrument reads of the amount of the two 
markers in each well and presents the results as a text file and a diagram. 
In figure 3-8 an example of a TaqMan diagram from C1797G genotyping 
is shown.  
 
Figure 3-8: Example of TaqMan genotyping diagram output. The G 
allele signal is shown on the Y axis and the C allele signal on the X axis. 
Blue = G/G, red = C/C and green = C/G. Black = non-DNA samples. The 
axis labels are related to signal strengths emitted from the different 
wells.  
A 10 % repetition was performed and all samples that were not genotyped 
by this method were further genotyped with the RFLP method.     
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3.3.3 Genotyping of C1797G with RFLP 
To verify TaqMan data some samples were genotyped with RFLP. This 
was also done for samples not successfully genotyped with TaqMan. PCR 
was run on the samples using specific C1797G primers to produce a 540 
bp fragment. This fragment was digested with the restriction 
endonuclease Hpy188I and the fragments made were separated on an 
agarose gel. The C/C genotype does not have a HPY188I restriction site 
and only shows one fragment. The G/G genotype gives rise to 2 fragments 
of 402 and 122 bp. In figure 3-9 an example of an agarose gel with 
different C1797G genotypes is shown.  
 
Figure 3-9: RFLP of C1797G. Arrows indicating bands to distinguish 
between the different genotypes at 524 bp, 402 bp and 122 bp, 
respectively. 
3.3.4 Risk association for lung cancer with SNP C1797G 
To elucidate any risk association between C1797G and lung cancer a 
series of lung cancer cases and matched controls were genotyped for SNP 
C1797G (chapter 2.4, 3.3.2 and 3.3.3). The risk associated for ach 
genotype was calculated with a logistic regression analysis. Characteristic 
of lung cancer cases and healthy controls are shown in table 3-9. The 
frequency of genotypes in the populations and the results from the logistic 
regression are shown in table 3-10.  
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Table 3-7: Characteristics of lung cancer cases and controls, all smokers.  
 
Table 3-8: Association of C1797G polymorphism with lung cancer. ORs 
are adjusted for smoking, age and sex.  
 
In this population the C/C genotype is more frequent and the G/G 
genotype rare. There is an overall protective effect of the heterozygous 
genotype C/G towards lung cancer in smokers. This effect is not 
significant in men, but significant in women. 
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3.4 Bioinformatic analysis for Putative transcription 
factor binding sites for SNP309 and C1797G 
For both SNPs putative transcription factor binding sites were elucidated 
in databases PROMO/Alggen and AliBaba [61,62]. This was done to find 
any possible transcription factor binding sites in the SNPs sequence 
region. The function of the different transcription factors are described in 
appendix IV.  
Since Bond et al had used AliBaba this database was also used. All 
putative transcription factor binding sites from the PROMO and AliBaba 
databases are shown in figure 3-10. 
 
Figure 3-10: All putative transcription factor binding sites for the 
SNP309 region. Those from AliBaba are marked. SNP309 shown in red. 
SNP309 sites found in PROMO and their dissimilarities are shown in 
table 3-7.  
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Table 3-9: Putative transcription factor binding to SNP309 region. 
Factors are showed with dissimilarities from the original binding sites 
and current binding sites. 
 
The difference between the two SNP309 genotypes is the addition of the 
putative Egr-1 binding site over SNP309 G/G. G/G also has a slightly 
smaller dissimilarity for Sp1 binding. T/T elongates the binding site for 
E2F-1. Also for T/T one Sp1 binding site from AliBaba is extended by 2 
nucleotides downstream from the SNP in addition to obtaining a third Sp1 
binding site.  
SNP C1797G was also analyzed in the PROMO database. Since Wang et 
al had used AliBaba this database was also included. All putative 
transcription factor binding sites from both databases are shown in figure 
3-11. 
 
Figure 3-11: All putative transcription factor binding sites in the SNP 
C1797G region. Those from AliBaba are marked. SNP marked in red. 
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For SNP C1797G sites found in PROMO are shown in table 3-8 with their 
respective dissimilarities.  
Table 3-10: Putative transcription factor binding sites from PROMO 
binding to C1797G. Factors are shown with dissimilarities and binding 
sites.  
 
The two C1797G genotypes differ in the putative binding of the C/EBP 
transcription factor. The G/G genotype has C/EBP binding and an 
extended Sp1 binding site. C/C has a slightly smaller dissimilarity for p53 
binding. 
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4. Discussion 
MDM2 SNP309 has been associated with several cancer forms, the results 
are ambiguous and vary with cancer type and patient/control ethnicity 
[56,63-72]. The first article describing a lung cancer - SNP309 association 
was published in 2006 by Hu et al where the authors showed no 
association with increased lung cancer risk in a Chinese population [73].  
Later Lind et al published a paper where they showed an association 
between NSCLC and SNP309. When they analyzed for gender a strong 
association in women was discovered [57]. Two meta-analyses have shown 
risk for lung cancer with SNP309. Also, a stronger association was seen 
for the Asian population [56,74]. 
In this thesis the aim of the study was to further elucidate the results 
from Lind et al with construction of SNP309-T/G-Luc vectors to 
investigate the relative transcriptional activity with T/T or G/G genotypes. 
4.1 Functional studies of SNP309 
Bond et al (who discovered SNP309) transfected the HeLa cell line with 
their SNP309 constructs and observed that the G/G construct was more 
transcriptionally active than T/T [54]. This goes against the results 
obtained in this thesis for the HeLa cell line. Here the T/T genotype leads 
to a more transcriptionally active Firefly luciferase gene. This more active 
T/T genotype trend was seen in all transfection experiments in lung cell 
lines (figure 3-4 A-E) and all were statistically significant. To rule out any 
tissue specific increase in transcription activity with T/T in lung cell lines, 
3 cell lines origination from cervix, breast and colon were also transfected. 
These also showed a higher transcriptional activity with the T/T genotype 
(figure 3-5 A-C) and these results were statistically significant. This 
excludes tissue specific effects on the SNP309-T/G-Luc constructs. When 
comparing expression in the different cell lines to endogenous SNP309 
genotype, gender and tissue origin there was no apparent pattern. 
The difference between the methods used by Bond et al and the present 
study are different expression vectors (pGL3 vs. pGL2). Bond et al do not 
describe which of the pGL2 vectors that has been used, but when 
assuming the use of pGL2 basic the two vectors differs in containing a 
synthetic poly A signal or not. The manufacturer (Promega) has 
redesigned pGL2 and created the pGL3 to obtain higher expression 
through the inclusion of the poly A signal. The other difference between 
the two projects is the length of the SNP containing region inserted into 
the expression vectors. Bond et al has used a SNP309 sequence available 
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from NCBI (showed in appendix II, slightly modified and 51 bp) in 
contrast to the 471 bp segment used in this project. There is a SNP 
located ~20 bp upstream of SNP309 (ID rs7484572) which is included in 
the SNP309-T/G-Luc constructs used in this project, whereas Bond et al 
has excluded this SNP from their constructs. This neighboring SNP may 
affect the promoter activity and thus give rise to the different 
experimental results. 
The results obtained from transient transfection in the present study are 
not comparable to any other studies. One study has indicated that the G/G 
genotype might be protective in women and another indicates that T/T 
gives longer patient survival [75,76]. 
4.2 The response of SNP309 genotypes to 17β-estradiol 
It has for some time been a focus on women and that they might have 
higher risk for lung cancer and other pulmonary diseases than men. Also 
there has been seen an increase in lung cancer incidences in women which 
might be related to a survival bias because of less cardiovascular disease 
in women compared to men [52,58,77]. 
Since women have been shown to have a higher lung cancer risk a 
possible role for estrogen was plausible. The aim of the study was to 
characterize SNP309s response to 17β-estradiol in the form of changed 
SNP309-T/G-Luc transcription activity. After 24 hours exposure to 17β-
estradiol the results showed no significant effect (figure 3-6A-D). As in 
only transfected cells, the T/T genotype still lead to a higher 
transcriptional activity compared to G/G. There might be a trend towards 
increased transcriptional activity from both constructs in the presence of 
10 nM 17β-estradiol. The female cell line NCI-H2009 shows a slight 
decrease in transcriptional activity with the G/G genotype with 10nM 17β-
estradiol. The immortalized cell lines BEAS-2B and BEP-2D showed no 
specific change and the BEP-2D cell line showed no difference in 
transcriptional activity between the two genotypes. All cell lines express 
ERβ, but A549 and NCI-H2009 are ERα negative whereas BEAS-2B and 
BEP-2D are partly positive [17]. 
Estrogen is a known inducer of cell proliferation and differentiation in the 
lung and its receptor is a transcription factor. It is therefore likely that 
estrogen is involved in lung tumorigenesis [58]. The presence of ERα has 
been associated with phase I enzymes such as CYP, CYP1B1 can 
metabolize Estradiol to a potentially mutagenic compound in addition to 
bioactivation of other carcinogens. Fasco et al has shown that ERα is more 
expressed in female lung tumors and in normal tissue than in male tissue 
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[78]. Dougherty et al showed that lung adenocarcinoma cell lines 
proliferate in response to Estradiol [16]. There are studies indicating that 
ERα is a more potent activator of estrogen responsive elements than its 
family member ERβ. It has also been observed that ERα is a better 
activator of Sp1 driven genes and this might be the interaction that 
elevates the expression. Still it is unlikely that such few factors comprises 
the whole picture when investigating the regulation of transcriptional 
activity from a gene [55]. 
Both ERα and ERβ physically interacts with the transcription factor 
Sp1[79]. It has been shown that MDM2 physically interacts with ERα. In 
an in vitro study it was observed that ERα and MDM2 form a complex 
which induces transcription from estrogen responsive genes [15]. There 
are evidences that suggest that MDM2 might be the factor involved in 
ERα turnover in the presence of Estradiol. ERα interacts with MDM2 in a 
complex with p53 and these two proteins are required for Estradiol 
dependent down-regulation of ERα [14]. In addition to this, the levels of 
p53 and MDM2 have been shown to increase with estrogen present. It has 
been suggested that when MDM2 is over-expressed it is involved in a 
ligand-independent turnover of ERα and that MDM2 ubiquitinates ERα 
[80]. 
Bond et al [81] has shown that SNP309 G/G women have about 13 years 
earlier age of onset for diffuse large B cell lymphoma (DLCBL). Estrogen 
has been proposed as the interacting factor since women who have been 
exposed to estrogens has altered risks for DLCBL in addition to that 
many DLCBLs are ER positive. Bond et al therefore investigated if pre-
menopausal women had lower age of onset due to SNP309 effect on the 
estrogen pathway. They found that no T/T women were diagnosed with 
DLCBL before the age of 55 in contrast to G/G women where half of them 
already had a DLCBL diagnosis at the same age. The authors concluded 
that estrogen may be the factor that allows SNP309 to accelerate DLCBL 
tumor formation.  This same effect has been documented for soft tissue 
sarcomas and breast carcinomas in women with a 14 year earlier age at 
diagnosis and that tumors were ER positive. In breast carcinomas only 
the patients with ER positive tumors showed an association with earlier 
age at diagnosis. Bond et al concluded that an active estrogen signaling 
pathway affects the G allele of SNP309 to accelerate tumor formation in 
women [81]. 
There might be an estrogen effect in the female cell line NCI-H2009, but 
this cannot be due to ERα since the cell line does not express this subtype 
of ER. The immortalized cell lines, which are partly positive for ERα 
show, a reduced difference (BEAS-2B) and no difference (BEP-2D) in 
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expression from the two constructs and this might be the effect of ERα on 
the SNP309-G/G-Luc promoter region. 
4.3 Endogenous MDM2 levels 
Bond et al investigated the endogenous levels of MDM2 in cell lines 
genotyped to be homozygous T/T or G/G and observed lower MDM2 levels 
in the T/T cell lines. They have genotyped the NCI-H460 cell line to be 
homozygous T/T. Genotyping data in this project contradicts this and 
show that this cell line is heterozygous (figure 3-7). To confirm the 
genotype, the cell line DNA was sequenced and the T/G genotype verified 
(data not shown). In the experiment where endogenous Sp1 is reduced by 
treatment with the RNA synthesis inhibitor Mithramycin A, the NCI-
H460 cell line deviates from the other T/T cell line and shows little 
reduction in MDM2 levels. This may be due to the incorrect genotyping of 
this cell line [54]. 
4.4 Transcription factor binding sites and SNP309 
When examining the sequence area around SNP309 Bond et al [54] found 
a putative Sp1 transcription factor binding site which in the presence of 
the G/G genotype was elongated by one nucleotide. This was found in the 
AliBaba transcription factor database. I was unable to replicate this 
finding in the PROMO/Transfac database, but observed a slightly 
decreased dissimilarity for binding with the G/G genotype present (figure 
3-10). When trying the AliBaba database the putative Sp1 binding site 
was not extended by one nucleotide to include the G/G genotype of 
SNP309, but extended with 2 nucleotides in the other direction with the 
T/T genotype present. The AliBaba database revealed an additional 
binding site with G/G present for the transcription factor Egr-1. Bond et 
al verified their Sp1 binding site results with EMSA. This showed more 
binding of Sp1 to G/G both with purified Sp1 and protein extract from the 
cell line HeLa. They further verified this by ChiP and detected bound Sp1 
to the P2 promoter in a SNP309 G/G cell line but this was not compared to 
the Sp1 amount bound in a T/T cell line. 
Bond et al further wanted to elucidate Sp1 involvement in P2 activity. 
They used their luciferase expression vector with the SNP309 G/G or T/T. 
These were co-transfected with a Sp1 expression vector in a Sp1 deficient 
cell line. Both SNP309 constructs were stimulated with increasing 
amounts of Sp1, but G/G more than T/T. The SNP309 sequences used by 
Bond et al contained several Sp1 binding sites and even though they 
observed increased binding of Sp1 to SNP309 G/G this cannot be 
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attributed to an extended Sp1 binding site since this cannot be replicated 
in the AliBaba database. Furthermore the same database showed more 
binding sites for Sp1 with the T/T genotype. It should be mentioned that 
these transcription factor databases change continuously and the inability 
to replicate Bond et al findings of the elongated Sp1 site may be due to 
updates of these databases. 
The neighboring SNP to SNP309 is a C/G transition. This SNP also has 
different putative transcription factor binding sites as shown in figure 4-1.  
 
Figure 4-1: Transcription factor binding sites for SNP ~20 bp upstream 
of SNP309. From the AliBaba database. 
With the C/C genotype the Sp1 binding site is extended, but for the G/G 
genotype several other transcription factor binding sites appear. Oct-1 
and ETF are transcription factors not directly involved in growth and 
differentiation. Transcription factors c-Myc, AP-2alph and NF-muE1 are 
involved in growth and differentiation (appendix IV). In the constructs 
made in the present study this SNP has the G/G genotype (sequencing 
results appendix II). If these are linked (SNP309T/T to SNP G/G) the 
additional transcription factors might contribute to the elevated 
transcriptional activity from the SNP309-T/T-Luc construct.  
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4.5 Association of the C1797G SNP with lung cancer 
Wang et al [53] recently identified a new SNP in MDM2 P1 which was 
shown to be functional. They also found an association between this SNP 
and risk of developing bladder cancer in a Chinese population. Since this 
SNP is also located in a MDM2 promoter region it can possibly affect 
MDM2 transcription. Therefore it was desirable to investigate its effect on 
lung cancer risk. The genotype distribution in this Norwegian population 
showed that the C/C and G/G genotypes were only slightly different with a 
higher frequency of C/C individuals. There was no pattern seen regarding 
difference in genotype distribution between cases and controls. According 
to the NCBI database the genotype distribution varies between the 
different populations (table 1-2). The G allele (rare) was shown by Wang 
et al to be associated with higher MDM2 mRNA levels. 
Individuals carrying the heterozygous genotype in the present study 
showed a low OR, especially in women and this was statistical significant. 
This might indicate a lung cancer protective genotype, particularly for 
smoking women. 
Wang et al also showed that the C/EBP transcription factor binds the G/G 
genotype of C1797G. By bioinformatic analysis this finding could be 
replicated, but in addition an extended Sp1 binding site was discovered 
(figure 3-11). The putative binding site for p53 had a slight decreased 
dissimilarity when binding to the C/C genotype of C1797G. These putative 
transcription factor binding sites for G/G may explain the increased risk 
of cancer with an increased MDM2 transcriptional activity which again 
leads to p53 attenuation 
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5. Conclusion and future work 
The persistent higher SNP309-T/T-Luc activity is the opposite from the 
hypothesis stating that the expected was a more transcriptionally active 
G/G genotype. This can be the result of the neighboring SNP or from the 
additional E2F and elongated Sp1 factor binding site with the T/T 
genotype. The G/G genotype shows the estimation of another binding site 
for Egr-1 and shorter E2F-1/Sp1 binding sites. The two SNPs separated 
by ~20 bp are most likely linked and contribute together to regulate P2 
activity. To characterize the individual SNPs effect on the MDM2 P2 
promoter new constructs should be made. The results obtained here must 
be further elucidated with determination of in vitro transcription factor 
binding for example by performing EMSA to investigate transcription 
factor binding to the SNP309 region. Characterization of endogenous 
MDM2 levels compared to SNP309 genotype for cell lines located at NIOH 
(National Institute of Occupational Health) might also help to map the 
SNP309 effect on MDM2.  
In regard to estrogen responsiveness there was no significant effect 
observed. To ensure that the lack of ERα in the female lung cancer cell 
line NCI-H2009 is not the reason that estrogen responsiveness was not 
detected additional female ERα positive cell lines needs to be studied. It 
also would be useful to investigate the possible Sp1-ERα-SNP309 
interaction since Sp1 and ERα has been observed in complex and that 
both ERα and Sp1 interacts with MDM2. 
The new C1797G SNP was discovered at the end of this project. Since this 
also is a functional SNP in the MDM2 promoter region it was included in 
the project. There was not found an increased risk for lung cancer in this 
population, but the heterozygous genotype is likely to be protective in 
smoking women. Functional studies with this SNP needs to be performed. 
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Appendix I 
Enzymes 
Enzyme Manufacturer Buffer 
HotFirePol DNA polymerase Solis BioDyne  B2 10X reaction buffer 
T4 DNA ligase New England Biolabs T4 DNA ligase buffer 
 
Restriction enzymes 
Enzyme Manufacturer Buffer 
BglII New England Biolabs NEB buffer 3 
Hpy188I New England Biolabs NEB buffer 4 
MluI New England Biolabs NEB buffer 3 
MspA1I New England Biolabs NEB buffer 4 / BSA 
 
Bacteria 
E.coli  DH5α F’Iq from New England Biolabs with following gene specifications:  
F' proA+B+ lacIq Δ(lacZ)M15 zzf::Tn10 (TetR)/fhuA2Δ(argF-lacZ)U169 phoA glnV44 Φ80 
Δ(lacZ)M15 gyrA96 recA1 relA1 endA1 thi-1 hsdR17. 
Cell lines 
Cell line Media Tissue origin Gender Distributor 
BL15, BL78, 
BL193, BL1672, 
BL2009. 
RPMI 1640 w/ 5 % 
FBS 
Blood 
lymphocytes? 
Same person as 
Hcc (15, 78, 193) 
and H2009. 
BL1672 is male. 
ATCC 
A549 DMEM/F12 w/10 
% FBS 
Lung adeno Male ATCC 
BEAS-2B LHC-9 w/ 4 % BSA Lung, SV40 
immortalized 
Male ATCC 
BEP-2D LHC-9 w/ 4 % BSA Lung, HPV 
immortalized 
Male ATCC 
Hcc78 (Scc78), 
Hcc193 (Scc193) 
HITES w/ 5 % FBS Lung adeno Male ATCC 
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HCT116 McCoy w/ 10 % 
FBS 
Colon Male ATCC 
HeLa DMEM/F12 w/ 10 
% FBS 
Cervix Female ATCC 
NCI-H2009 HITES w/ 5 % FBS Lung adeno Female ATCC 
NCI-H460 RPMI 1640 w/ 5 % 
FBS 
Lung large cell Male ATCC 
MCF-7 RPMI 1640 ++ w/ 
10 % FBS 
Breast carcinoma Female ATCC 
MDA-MB-231 RPMI 1640 ++ w/ 
10 % FBS 
Breast carcinoma Female ATCC 
PC3 RPMI 1640 + w/ 10 
% FBS 
Prostate Male ATCC 
THP-1 RPMI 1640 +++ w/ 
10 % FBS 
Acute monocytic 
leukemia 
Male ATCC 
 
Kits 
Applied Biosystems 
Sequencing reaction components supplied in the BigDye® Terminator v1.1 Cycle Sequencing Kit. 
Invitrogen 
Quantification of dsDNA with Invitrogen’s Quant-iT™ PicoGreen® dsDNA Reagent. 
MilliPore: 
Up-concentration of purified PCR fragments with Microcon® YM-30 Centrifugal Filter Units. 
Qiagen: 
PCR reaction cleanup with QIAquick nucleotide removal kit. 
Plasmid isolation with QIAprep Spin Miniprep kit and QIAprep Endofree Maxiprep kit. 
Removal of unincorporated ddNTPs with DyeEx 2.0 Spin kit  
Instruments 
Luminometers    Turner biosystems Modulus microplate. 
     Packard Fusion TM plate analyzer.    
Sequencing instrument   ABI prism 310 genetic analyzer 
Spectrophotometer   Eppendorf biophotometer 
TaqMan instrument   ABI prism 7900 HT sequence detection system 
Thermal cyclers  Peltier Thermal Cycler DYAD™ DNA engine 96 wells.  
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Peltier Thermal Gradient Cycler PTC-200 384 wells 
Chemicals 
Acetic acid (glacial)  Merck 
Agarose (SeaKem GTG)  Lonza 
Ampicillin sodium salt  Kebolab 
Bacto™-agar   BD 
Bacto™-tryptone  BD 
Boric acid   Sigma 
Bovine serum albumin  Sigma 
Bromophenol blue  Chroma-
Gesellschaft 
Collagen   Vitrogen 
Dubecco’s Modified Eagle                            
Medium    Gibco 
Dimethyl sulphoxide 99% Sigma  
dNTPs    Quanta 
EDTA (Triplex III)  Merck 
Etyleneglycol bis                 
NNNN-tetra acetrate   Sigma 
Epidermal Growth Factor Sigma 
Ethidium bromide  Biorad 
Ethanol (rectified, absolute) Arcus 
Fetal bovine serum  Gibco 
Fugene transfection reagent Roche 
Fungizone   Gibco 
Gentamicin   Invitrogen 
Glucose    Sigma 
L-Glutamine   Sigma 
Glycerol 99,5 %   Aldrich 
Ham’s F12   Gibco 
Hydrocortisone   Sigma 
HCl    Merck 
HEPES    Sigma 
Insulin    Sigma 
KCl    Merck 
Leibovitz’s L15 media  Invitrogen 
Ladders   New England Biolabs  
LHC-9    Invitrogen 
Lipofectamin reagent   Invitrogen 
McCoy 5A media  Invitrogen 
NaCl    Merck 
NaHCO3   Merck 
NaHPO4 · H2O   Merck 
NEB D1 transpass New England Biolabs 
Phenol red   Sigma 
Plus reagent     Invitrogen 
Propane-2-ol (isopropanol) Merck 
Penicillin-Streptomyocin  Gibco 
RPMI  1640   Gibco  
Selenium (Na2SeO3)  Sigma 
Sodium puryvate  Sigma 
Transferrin   Sigma 
Tris-base 7-9®   Sigma 
Trypsin    Sigma 
Yeast extract   DIFCO 
Solutions 
All solutions are made with ddH2O and sterile filtered before use where needed.  
AF (antibiotic freeze media) 
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76 % L15 media 2 % 1M HEPES, 2 % PS, 20 % FBS.  
BSA (bovine serum albumin) 1 mg/ml stock 
100 mg BSA, 100 ml HBS. 
DMSO (dimethyl sulphoxide) for cell culture storage 
50 % L15 media, 2 % 1 M HEPES, 8 % DMSO, 40 % FBS. EDTA 
EDTA 0,5 M disodium dihydrate (ethylenediaminetetraacetic acid) 50 ml 
9,3 g EDTA, 50 ml H2O, pH adjusted to 8.  
EGF (epidermal growht factor) 10 μg/ml 
200 μg EGF, 2 ml BSA solution, 18 ml HBS.  
EGTA (etyleneglycol bis NNNN-tetra acetrate) 2 % 
200 mg EGTA, 100 ml HBS.  
FBS (fetal bovine serum)  
Heat inactivated at 56 ºC for 45 minutes.  
Glucose 200 mg/ml 
20 g glucose, 100 ml H2O.  
Glutamine 200 mM 
2,9 g glutamine, 100 ml H2O. 
HBS (HEPES buffered saline) 
4,76 g HEPES, 7,07 g NaCl, 0,20 g KCl, 1,70 g glucose, 1,94 g NaHPO4 · H2O, 1,04 ml 0,12 % phenol red, 
H2O to 1 l.  
HC (hydrocortisone) 1,0 mM 
7,2 mg HC, 20 ml rectified ethanol.  
Insulin 4 mg/ml 
100 mg insulin, 25 ml 4 mM HCl.  
NaHCO3 (carbonate) 7,5 % 
7,5 g NaHCO3, 100 ml H2O. 
PBS (phosphate buffered saline) 
7,07 g NaCl, 0,20 g KCl, 1,94 g NaHPO4 · H2O, 1,04 ml 0,12 % phenol red, H2O to 1 l.  
PET (PVP, EGTA, Trypsin stock) 
1 % PVP, 1 % EGTA, 0,2 % Trypsin stock, 7,8 % HBS.  
Phenol red 125 mg/ml 
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125 phenol red, 360 μl 1N NaOH, 100 ml H2O.  
PVP ( Polyvinyl pyrrolodion) 10 % 
10 g PVP, 100 ml HBS.  
Selenium (Na2SeO3) 0,1 M, 100 ml 
1,73 g Na2SeO3, 100 ml H2O.  
TAE buffer (Tris-acetate-EDTA buffer) 50 X, 1L 
242 g Tris base, 57,1 ml glacial acetic acid, 100 ml 0,5 M EDTA pH 8.  
TBE buffer (Tris-borate-EDTA buffer) 5 X , 1L 
54 g Tris base, 27,5 g boric acid, 20 ml 0,5 M EDTA pH 8. 
TE buffer (Tris-EDTA buffer) 10 X, pH 8 
100 med mer Tris-Cl pH 8, 10 med mer EDTA pH 8. 
TF (transferrin) 5 mg/ml 
500 mg transferrin, 10 ml BSA stock, 90 ml HBS.  
Tris-Cl 1M pH 8, 1L 
121,1 g Tris base, 42 ml HCl, H2O to 1L.  
Trypsin 1 % 
50 mg trypsin, 5 ml HBS.  
Collagen solution for petri dish coating 0,03 mg/ml 
1 % Collagen solution 3,13 mg/ml, 99 % HBS. 
Bacteria culture media and agar: 
Luria-Bertani LB 1L 
10 g tryptone, 5 g yeast extract, 10 g NaCl, H2O to 1L. Autoclaved.  
LB-agar 
10 g tryptone, 5 g yeast extract, 10 g NaCl, 15 g Bactoagar, H2O to 1L. Autoclaved.  
LB-Ampicillin 
LB-media and Ampicillin to the concentration of 100 µg/ml added after autoclavation and cooling to 50 °C. 
SOC 1L 
20 g tryptone, 5 g yeast extract, 0,5 g NaCl, 20 ml 1M glucose added after autoclavation. 
Cell culture media 
After 2 months, 5 ml of L-glutamine was added to the media. 
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DMEM/F12 w/ 10 % FBS 
 500 ml DMEM/F12 
 7,5 ml HEPES 
 625 μl Insulin 
 50 μl HC 
 500 μl EGF 
 145 μl Selenium 
 5 ml PS 
 500 μl TF 
 50 ml FBS (10 %) 
 
HITES w/ 5 % FBS 
 500 ml RPMI 1640 
 25 ml FBS  
 5 ml PS  
 5 μl HC 
 625 μl Insulin 
 1 ml TF 
 300 μl Selenium 
 5 ml HEPES 
RPMI 1640 w/ 5 % FBS 
 500 ml RPMI 1640 
 500 μl EGF 
 250 μl HC 
 500 μl Insulin 
 5 ml PS 
 25 ml FBS 
 
RPMI 1640 + w/ 10 % FBS PC3 
 500 ml RPMI 1640  
 5 ml PS 
 50 ml FBS  
 
RPMI 1640 ++ w/ 10 % FBS MCF-7 
 500 ml RPMI 1640  
 50 ml FBS  
 5 ml Natriumpyruvat  
 5 ml PS  
 
RPMI 1640 +++ w / 10 % FBS THP-1 
 500 ml RPMI 1640 
 5,5 ml HEPES 
 55 mg Sodium pyruvate 
 550 μl Gentamicin 
 50 ml FBS  
 
LHC-9 
 500 ml LHC-9 
 20 ml BSA 
 (2,5 ml Fungizone) 
 
McCoy 
 500 ml McCoy 
 50 ml FBS 
 
 
 
 
 
 
 
 
 
 
DNA ladders Low molecular, 100 bp and 1kb ladders, respectively.  
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Appendix II 
Vector maps 
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Primers 
SNP309 forward: 5’-ACGCGTTGCGGAGGTTTTGTTGGAC-3’ 
SNP309 reverse: 5’-AGATCTAAGCAAGTCGGTGCTTACCTG-3’ 
RV3:   5´-CTAGCAAAATAGGCTGTCCC-3´ 
GL2:   5´-CTTTATGTTTTTGGCGTCTTCCA-3´ 
C1797G forward: 5-GCACGCGTCTAAAAGCGCAGAGTAACCG-3’ 
C1796G reverse: 5’-GCAGATCTCATCCGGGCATTTGTG-3’ 
SNP sequences: 
SNP309 
GTGTGCCTGTGTGCACTTGGGTCTGT[C/T]GGATGACATTGGGTCACTGTGTCTG 
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C1797G  
GCGGCCAACACCCCCACCCCGCCTCA[C/G]AGCCCGCCGCGCCCGCGGGGCGACA   
Neighboring SNP to SNP309 
GGGAGTTCAGGGTAAAGGTCACGGGG[C/G]CCGGGGGCTGCGGGGCCGCTTCGGC 
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Appendix III 
Sequencing 
Primers are marked in pink/blue and SNP309 is marked in green. Neighbor SNP is marked in 
grey.  
SNP309-G/G-Luc complement sequence.  
AGGGSTMYAARGGTACCGGGAATGCCAAGCTTACTTAGATCGCAGATCTAAGCAAGTCGGT
GCTTACCTGGATCAGCWKAGAAAAAGTGGCGTGCATCCGTGCCCACAGGTCTACCCTCCAA
TCGCCACTGAACACAGCTGGGAAAATGCATGGTTTAAATAGCCCCAGCTGGAGACAAGTCA
GGACTTAACTCCTTTTACTGCAGTTTCGGAACGTGTCTGAACTTGACCAGCTCAAGAGGAAA
AGCTGAGTCAACCTGCCCACTGAACCGGCCCAATCCCGCCCAGACTACGCGCAGCGTTCAC
ACTAGTGACCCGACAGGCACCTGCGATCATCCGGACCTCCCGCGCCGCAGCGGCCCCGCAG
CCCCCGGCCCCCGTGACCTTTACCCTGAACTCCCGCGGAGACCTCCGAACCACCCCCACCC
CCACCGCCGCGAGAGCCGTCCGAAATCCCGCCCTCCTCCCTGGCGGCGACTGCCTAGCCCC
AGTCCAACAAAACCTCCGCAACGCGTAAGAGCTCGGTACCTATCGATAGAGAAATGTTCTG
GCACCTGCACTTGCACTGGGGACAGCCTATTTTGCTAGTTTGTTTTGTTTCGTTTTGTTTTGA
TGGAGAGCGTATGTTAGTACTATCGATTCACACAAAAAACCAACACACAGATGTAATGAAAA
TAAAGATATTTTATTGCGGCCGCTCCAAGTACCTCCCGTACCTTAATATTACTTACTTATCAT
GGTAGCTTGGGCTGGCGTAATARCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAKTTGC
GCAGCCTGAATGGCGAATGCAAATTGTAAGCGTTAATATTTTGTAAAATTCGCGTAAATTTT
TGTTAATCAGCTCATTTTTTAACCAATAGGCGAAATCGGSAAATCCCTTAWAATMAAAGAAT
AGMYYGAKATAGKGKTGAGTGTTGTTCMAGTTTGAACAAGAGTCCACTATTAAARAWSKG
AMTYCAACGTYAAACGGCGAAAAACGTYTATCWGGYGATGCCCWCTAYCTGACCMTYMCC
TCATYAMGTTTTTGGGGTCMRGKGKCTAATYACTAMACKGAAWCCTTAASGGASCCYCGW
YTCAGCTTKAKGGGWAATKCTGCTACTTGTGTGASAYGAAAGGAWAWAGTMWARGWACK
SGCTYAGGYKYTGCTWYKTMYKGACACCSCWCSWACWYMCMYAYCYCYCT 
SNP309-T/T-Luc complement sequence. 
TGGGYMWMAMRKTACCGGATGCCAGCTTACTTAGATCGCAGATCTAAGCAAGTCGGTGCT
TACCTGGATCMSWWGTKAAAAAGTGGCGTGCGTCCGTGCCCACAGGTCTACCCTCCAATC
GCCACTGAACACAGCTGGGAAAATGCATGGTTTAAATAGCCCCAGCTGGAGACAAGTCAGG
ACTTAACTCCTTTTACTGCAKTTTCGGAACGTGTCTGAACTTGACCAGCTCAAGAGGAAAAG
CTGAGTCAACCTGCCCACTGAACCGGCCCAATCCCGCCCAGACTACGCGCAGCGTTCACAC
TAGTGACCCGACAGGCACCTGCGATCATCCGGACCTCCCGCGCCGAAGCGGCCCCGCAGCC
CCCGGCCCCCGTGACCTTTACCCTGAACTCCCGCGGAGACCTCCGAACCACCCCCACCCCC
ACCGCCGCGAGAGCCGTCCGAAATCCCGCCCTCCTCCCTGGCGGCGACTGCCTAGCCCCAG
TCCAACAAAACCTCCGCAACGCGTAAGAGCTCGGTACCTATCGATAGAGAAATGTTCTGGC
ACCTGCACTTGYACTGGGRACAGCCTATTTTGCTAGTTTGTTTTGTTTCGTTTTGTTTTGATG
GASAGCGTATGTTAGTACTATCGATTCACACWAAAAACCAACACACAGATGYAATGAAAATA
AAGATATTTTTATTGYRGCCGCTCCAAGTACCTCCCGTAYCTTAATATTACTTACTTATCWT
GKTAKCTTGGGGTGGCGTAATAGCGAKKGGCCCGCWCGATCGCCCTTCYCACAGTTGYGC
AGCCTGAATGRCGAATGCMAATTGTASWGTTAWTATTTTKGTTAAMTTCSCTTAAATTTTGT
WAATCARSTYAWTTTTTSMCARTAGGYCWAATSGCAAAATCYCTTWTAMTCWWAAGAATW
ARMCRAATMGGKTSAATGTGTTCWRTTGGAACAMRAATCCMCWATWAGRAMKGGGACTC
WACGYMAAKGGCGAYARCGTCWTCWGGSRAWYGKCCWTWASKGWAACWCTMWCCTAA
MMRKTTTTTKSGKCCAAGKGYCKTAAGSAMTWWATTSKAATCCTMSAGGARYCCCCWAYT
TWWAMTTAYGSGYAAASCCKKTAACTSGKC 
Transfection 
A549 
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 Luciferase Renilla Ratio  Luciferase Renilla Ratio 
G 414000,00 3931,00 105,32  68740,00 1100,00 62,49 
G 429400,00 4344,00 98,85  73180,00 1058,00 69,17 
G 399900,00 3757,00 106,44  59580,00 1116,00 53,39 
Gj.snitt 414433,33 4010,67 103,54  67166,67 1091,33 61,68 
T 409000,00 3497,00 116,96  86400,00 1102,00 78,40 
T 441300,00 3660,00 120,57  93070,00 1144,00 81,35 
T 430900,00 3452,00 124,83  91570,00 1043,00 87,79 
Gj.snitt 427066,67 3536,33 120,79  90346,67 1096,33 82,52 
        
 Luciferase Renilla Ratio  
G 88840,00 1537,00 57,80  
G 116500,00 1595,00 73,04  
G 103700,00 1339,00 77,45  
Gj.snitt 103013,33 1490,33 69,43  
T 127100,00 1485,00 85,59  
T 139600,00 1479,00 94,39  
T 134700,00 1354,00 99,48  
Gj.snitt 133800,00 1439,33 93,15  
 
NCI-H2009 
 Luciferase Renilla Ratio  Luciferase Renilla Ratio 
G 702 2100 0,33428571  595 1124 0,52935943 
G 604 2270 0,2660793  600 1284 0,46728972 
G 213 6290 0,03386328  671 1278 0,52503912 
Gj.snitt 506,333333 3553,33333 0,21140943  622 1228,66667 0,50722942 
T 440 1537 0,28627196  1155 1454 0,79436039 
T 380 1226 0,30995106  1085 1587 0,6836799 
T 202 661 0,30559758  1153 1435 0,80348432 
Gj.snitt 340,666667 1141,33333 0,30060687  1131 1492 0,7605082 
        
 Luciferase Renilla Ratio  Luciferase Renilla Ratio 
G 730 2070 0,352657  519 1230 0,42195122 
G 719 2040 0,35245098  558 1290 0,43255814 
G 480 1494 0,32128514  643 1367 0,47037308 
Gj.snitt 643 1868 0,34213104  573,333333 1295,66667 0,44162748 
T 768 1495 0,51371237  701 1267 0,55327545 
T 939 1844 0,50921909  851 1376 0,6184593 
T 468 961 0,48699272  828 1238 0,66882068 
Gj.snitt 725 1433,33333 0,50330806  793,333333 1293,66667 0,61351848 
        
 Luciferase Renilla Ratio  Luciferase Renilla Ratio 
G 583 2030 0,28719212  508 1672 0,30382775 
G 527 1832 0,28766376  501 1639 0,30567419 
G 406 1589 0,25550661  406 1212 0,3349835 
Gj.snitt 505,333333 1817 0,27678749  471,666667 1507,66667 0,31482848 
T 367 956 0,38389121  540 1100 0,49090909 
T 234 659 0,35508346  596 1757 0,33921457 
T 410 1001 0,40959041  476 1105 0,43076923 
Gj.snitt 337 872 0,38285503  537,333333 1320,66667 0,42029763 
 
BEAS-2B 
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 Luciferase Renilla Ratio  Luciferase Renilla Ratio 
G 3842 711 5,40365682  1972 576 3,42361111 
G 4355 728 5,98214286  1682 509 3,30451866 
G 4928 856 5,75700935  2233 544 4,10477941 
Gj.snitt 4375 765 5,71895425  1962,33333 543 3,61387354 
T 8044 1055 7,62464455  3457 832 4,15504808 
T 6788 876 7,74885845  3075 717 4,28870293 
T 8527 914 9,32932166  3967 512 7,74804688 
Gj.snitt 7786,33333 948,333333 8,21054482  3499,66667 687 5,09412906 
        
 Luciferase Renilla Ratio  Luciferase Renilla Ratio 
G 2125 1497 1,41950568  2600 525 4,95238095 
G 1681 1392 1,20761494  1900 525 3,61904762 
G 1952 1472 1,32608696  2050 579 3,54058722 
Gj.snitt 1919,33333 1453,66667 1,32033937  2183,33333 543 4,0208717 
T 3487 1908 1,82756813  3898 556 7,01079137 
T 3864 2454 1,57457213  4456 567 7,85890653 
T 4057 2202 1,84241599  3197 534 5,98689139 
Gj.snitt 3802,66667 2188 1,73796466  3850,33333 552,333333 6,97103199 
 
BEP-2D 
 Luciferase Renilla Ratio  Luciferase Renilla Ratio 
G 4332 1597 2,7125861  7736 299 25,8729097 
G 5980 1615 3,70278638  10710 378 28,3333333 
G 3682 1394 2,64131994  11160 505 22,0990099 
Gj.snitt 4664,66667 1535,33333 3,01889747  9868,66667 394 25,4350843 
T 6783 1679 4,03990471  13110 440 29,7954545 
T 7986 1691 4,72264932  13230 543 24,3646409 
T 9721 2243 4,33392778  11730 415 28,2650602 
Gj.snitt 8163,33333 1871 4,36549393  12690 466 27,4750519 
        
        
 Luciferase Renilla Ratio  Luciferase Renilla Ratio 
G 3406 642 5,30529595  3757 265 14,1773585 
G 2695 585 4,60683761  589 90 6,54444444 
G 2781 575 4,83652174  1061 96 11,0520833 
Gj.snitt 2960,66667 600,666667 4,91621843  1802,33333 150,333333 10,5912954 
T 5424 710 7,63943662  3362 197 17,0659898 
T 4906 708 6,92937853  2790 161 17,3291925 
T 4619 543 8,50644567  2070 147 14,0816327 
Gj.snitt 4983 653,666667 7,69175361  2740,66667 168,333333 16,1589383 
        
     
 Luciferase Renilla Ratio  
G 10780 949 11,3593256  
G 13140 1017 12,920354  
G 12110 880 13,7613636  
Gj.snitt 12010 948,666667 12,6803477  
T 20290 1098 18,4790528  
T 23010 1217 18,9071487  
T 26430 1098 24,0710383  
Gj.snitt 23243,3333 1137,66667 20,4857466  
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NCI-H460 
 Luciferase Renilla Ratio  Luciferase Renilla Ratio 
G 13460 526 25,5893536  16930 659 25,6904401 
G 11680 522 22,3754789  11470 476 24,0966387 
G 8435 494 17,0748988  14290 514 27,8015564 
Gj.snitt 11191,6667 514 21,7736706  14230 549,666667 25,8884172 
T 17180 753 22,815405  23070 501 46,0479042 
T 17000 727 23,3837689  26360 637 41,3814757 
T 17590 612 28,7418301  25380 558 45,483871 
Gj.snitt 17256,6667 697,333333 24,7466539  24936,6667 565,333333 44,1096698 
        
      
 Luciferase Renilla Ratio  Luciferase Renilla Ratio 
G 7055 676 10,4363905  28260 753 37,5298805 
G 7096 429 16,5407925  26790 686 39,0524781 
G 4149 399 10,3984962  26510 748 35,4411765 
Gj.snitt 6100 501,333333 12,1675532  27186,6667 729 37,2930956 
T 13120 609 21,543514  62320 1131 55,1016799 
T 17760 779 22,7984596  63600 1104 57,6086957 
T 13600 798 17,0426065  71250 1494 47,6907631 
Gj.snitt 14826,6667 728,666667 20,347667  65723,3333 1243 52,8747654 
 
HeLa 
 Luciferase Renilla Ratio  Luciferase Renilla Ratio 
G 2254 4262 0,52885969  422 681 0,61967695 
G 2295 3548 0,64684329  803 984 0,81605691 
G 1444 2498 0,57806245  678 976 0,69467213 
Gj.snitt 1997,66667 3436 0,58139309  634,333333 880,333333 0,72056039 
T 4148 3781 1,09706427  1850 1360 1,36029412 
T 4776 4596 1,03916449  2085 1398 1,49141631 
T 4064 4163 0,97621907  1769 1284 1,37772586 
Gj.snitt 4329,33333 4180 1,03572568  1901,33333 1347,33333 1,41118258 
        
        
     Luciferase Renilla Ratio 
G 677 3070 0,22052117  857 1368 0,62646199 
G 1023 3689 0,27731092  920 1386 0,66378066 
G 784 2757 0,28436707  1140 1513 0,75346993 
Gj.snitt 828 3172 0,26103405  972,333333 1422,33333 0,68361847 
T 2239 6595 0,33949962  2714 2294 1,18308631 
T 2841 5743 0,49468919  3309 2141 1,54553947 
T 3151 5371 0,58666915  3799 2260 1,68097345 
Gj.snitt 2743,66667 5903 0,46479191  3274 2231,66667 1,46706497 
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MCF-7 
 Luciferase Renilla Ratio  Luciferase Renilla Ratio 
G 150400 1518 99,0777339  407100 5580 72,9569892 
G 130900 1488 87,9704301  399200 5478 72,8733114 
G 89420 991 90,2320888  254400 3575 71,1608392 
Gj.snitt 123573,333 1332,33333 92,4267509  353566,667 4877,66667 72,3303799 
T 200700 1957 102,554931  467800 3988 117,301906 
T 200100 1779 112,478921  444600 3732 119,131833 
T 165900 1744 95,1261468  535000 4729 113,13174 
Gj.snitt 188900 1826,66667 103,386666  482466,667 4149,66667 116,521826 
        
 Luciferase Renilla Ratio  Luciferase Renilla Ratio 
G 115000 1431 80,3633823  187600 2369 79,1895314 
G 149400 1840 81,1956522  242500 2871 84,4653431 
G 157100 1703 92,2489724  230000 2958 77,75524 
Gj.snitt 140500 1658 84,6026689  220033,333 2732,66667 80,4700382 
T 85720 906 94,6136865  313600 3468 90,4267589 
T 76320 903 84,5182724  308000 3418 90,1111761 
T 44880 465 96,516129  292100 3383 86,3434821 
Gj.snitt 68973,3333 758 91,882696  304566,667 3423 88,9604724 
 
HCT-116 
 Luciferase Renilla Ratio   Luciferase Renilla Ratio 
G 483500 54260 8,91079985   359000 87050 4,12406663 
G 500500 57560 8,6952745   336400 69610 4,83263899 
G 479700 55810 8,59523383   321200 66430 4,83516484 
Gj.snitt 487900 55876,6667 8,73376939   338866,667 74363,3333 4,59729015 
T 490300 41500 11,8144578   434700 75160 5,78366152 
T 759700 52480 14,4759909   467600 77650 6,02189311 
T 640200 52480 12,1989329   433800 72230 6,00581476 
Gj.snitt 630066,667 48820 12,8297939   445366,667 75013,3333 5,93712313 
         
 Luciferase Renilla Ratio   Luciferase Renilla Ratio 
G 145900 24960 5,84535256   330600 49550 6,67204844 
G 157700 28820 5,47189452   423200 63180 6,69832225 
G 164400 29450 5,58234295   443800 58180 7,62805088 
Gj.snitt 156000 27743,3333 5,63319668   399200 56970 6,99947386 
T 214900 27730 7,74972953   516200 50850 10,1514258 
T 242000 30050 8,05324459   526600 48180 10,9298464 
T 244100 26050 9,37044146   561400 55360 10,140896 
Gj.snitt 233666,667 27943,3333 8,39113853   534733,333 51463,3333 10,4073894 
 
Estrogen exposure 
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A549 
G 0 nM 68740 1100 62,4909091  T 0 nM 86400 1102 78,4029038 
G 0 nM 73180 1058 69,168242  T 0 nM 93070 1144 81,3548951 
G 0 nM 59580 1116 53,3870968  T 0 nM 91570 1043 87,7948226 
Gj.snitt 67166,6667 1091,33333 61,6820826  Gj.snitt 90346,6667 1096,33333 82,5175405 
G 1 nM 9987 348 28,6982759  T 1 nM 31670 404 78,3910891 
G 1 nM 9178 271 33,8671587  T 1 nM 23770 314 75,7006369 
G 1 nM 12550 441 28,4580499  T 1 nM 22940 346 66,300578 
Gj.snitt 10571,6667 353,333333 30,3411615  Gj.snitt 26126,6667 354,666667 73,4641014 
G 10 nM 9512 200 47,56  T 10 nM 22700 167 135,928144 
G 10 nM 17080 311 54,9196141  T 10 nM 13490 109 123,761468 
G 10 nM 28620 381 75,1181102  T 10 nM 11230 107 104,953271 
Gj.snitt 18404 297,333333 59,1992415  Gj.snitt 15806,6667 127,666667 121,547628 
         
G 0 nM 34600 294 117,687075  T 0 nM 23920 281 85,1245552 
G 0 nM 21390 245 87,3061224  T 0 nM 30580 289 105,813149 
G 0 nM 26490 252 105,119048  T 0 nM 25100 203 123,64532 
Gj.snitt 27493,3333 263,666667 103,370748  Gj.snitt 26533,3333 257,666667 104,861008 
G 1 nM 110700 1509 73,359841  T 1 nM 157200 1198 131,218698 
G 1 nM 118100 1350 87,4814815  T 1 nM 168600 1723 97,8525827 
G 1 nM 154200 2460 62,6829268  T 1 nM 284500 2447 116,264814 
Gj.snitt 127666,667 1773 74,5080831  Gj.snitt 203433,333 1789,33333 115,112032 
G 10 nM 168500 1959 86,0132721  T 10 nM 279200 2910 95,9450172 
G 10 nM 441700 5110 86,4383562  T 10 nM 365200 2537 143,949547 
G 10 nM 221400 2652 83,4841629  T 10 nM 204900 2039 100,490436 
Gj.snitt 277200 3240,33333 85,3119304  Gj.snitt 283100 2495,33333 113,461667 
         
G 0 nM 88840 1537 57,8009109  T 0 nM 127100 1485 85,5892256 
G 0 nM 116500 1595 73,0407524  T 0 nM 139600 1479 94,3881001 
G 0 nM 103700 1339 77,4458551  T 0 nM 134700 1354 99,4830133 
Gj.snitt 103013,333 1490,33333 69,4291728  Gj.snitt 133800 1439,33333 93,1534463 
G 1 nM 53180 974 54,5995893  T 1 nM 144000 1574 91,4866582 
G 1 nM 110200 1426 77,2791024  T 1 nM 123900 1066 116,228893 
G 1 nM 41820 695 60,1726619  T 1 nM 126600 1458 86,8312757 
Gj.snitt 68400 1031,66667 64,0171179  Gj.snitt 131500 1366 98,1822757 
G 10 nM 142300 2093 67,9885332  T 10 nM 289500 2492 116,17175 
G 10 nM 182400 2075 87,9036145  T 10 nM 206300 2145 96,1771562 
G 10 nM 146000 1679 86,9565217  T 10 nM 121600 1312 92,6829268 
Gj.snitt 156900 1949 80,9495565  Gj.snitt 205800 1983 101,677278 
         
G 0 nM 414000 3931 105,316713  T 0 nM 409000 3497 116,957392 
G 0 nM 429400 4344 98,8489871  T 0 nM 441300 3660 120,57377 
G 0 nM 399900 3757 106,44131  T 0 nM 430900 3452 124,826188 
Gj.snitt 414433,333 4010,66667 103,53567  Gj.snitt 427066,667 3536,33333 120,785783 
G 1 nM 452300 3902 115,914915  T 1 nM 440400 3006 146,506986 
G 1 nM 332900 3073 108,330622  T 1 nM 483600 3060 158,039216 
G 1 nM 259600 2300 112,869565  T 1 nM 228000 1698 134,275618 
Gj.snitt 348266,667 3091,66667 112,371701  Gj.snitt 384000 2588 146,27394 
G 10 nM 79130 646 122,49226  T 10 nM 83080 603 137,777778 
G 10 nM 70570 532 132,650376  T 10 nM 143800 916 156,9869 
G 10 nM 158000 1292 122,291022  T 10 nM 129400 864 149,768519 
Appendix 
97 
 
Gj.snitt 102566,667 823,333333 125,811219  Gj.snitt 118760 794,333333 148,177732 
         
G 0 nM 186200 1025 181,658537  T 0 nM 131300 648 202,623457 
G 0 nM 163300 963 169,574247  T 0 nM 164000 640 256,25 
G 0 nM 149000 866 172,055427  T 0 nM 51740 272 190,220588 
Gj.snitt 166166,667 951,333333 174,429404  Gj.snitt 115680 520 216,364682 
G 1 nM 158300 988 160,222672  T 1 nM 96170 464 207,262931 
G 1 nM 121800 686 177,55102  T 1 nM 103200 542 190,405904 
G 1 nM 30900 461 67,0281996  T 1 nM 88900 604 147,18543 
Gj.snitt 103666,667 711,666667 134,933964  Gj.snitt 96090 536,666667 181,618089 
G 10 nM 84440 561 150,516934  T 10 nM 165100 804 205,348259 
G 10 nM 32890 247 133,157895  T 10 nM 74790 365 204,90411 
G 10 nM 67870 388 174,92268  T 10 nM 45950 305 150,655738 
Gj.snitt 61733,3333 398,666667 152,865836  Gj.snitt 95280 491,333333 186,969369 
 
NCI-H2009 
 Luciferase Renilla Ratio   Luciferase Renilla Ratio 
G 0 nM 730 2070 0,352657  T 0 nm 768 1495 0,51371237 
G 0 nM 719 2040 0,35245098  T 0 nm 939 1844 0,50921909 
G 0 nM 480 1494 0,32128514  T 0 nm 468 961 0,48699272 
Gj.snitt 643 1868 0,34213104  Gj.snitt 725 1433,33333 0,50330806 
G 1 nM 274 1043 0,26270374  T 1 nM 871 1885 0,46206897 
G 1 nM 280 1219 0,22969647  T 1 nM 932 1998 0,46646647 
G 1 nM 158 1146 0,13787086  T 1 nM 815 1825 0,44657534 
Gj.snitt 237,333333 1136 0,21009036  Gj.snitt 872,666667 1902,66667 0,45837026 
G 10 nM 153 651 0,23502304  T 10 nM 600 1230 0,48780488 
G 10 nM 99 885 0,11186441  T 10 nM 744 1332 0,55855856 
G 10 nM 88 616 0,14285714  T 10 nM 604 1139 0,53028973 
Gj.snitt 113,333333 717,333333 0,15799257  Gj.snitt 649,333333 1233,66667 0,52555105 
         
 Luciferase Renilla Ratio   Luciferase Renilla Ratio 
G 0 nM 481 1122 0,42869875  T 0 nM 369 758 0,48680739 
G 0 nM 613 1495 0,41003344  T 0 nM 391 689 0,56748911 
G 0 nM 671 1315 0,51026616  T 0 nM 413 820 0,50365854 
Gj.snitt 588,333333 1310,66667 0,44966612  Gj.snitt 391 755,666667 0,51931835 
G 1 nM 323 813 0,39729397  T 1 nM 357 734 0,48637602 
G 1 nM 323 807 0,40024783  T 1 nM 409 629 0,65023847 
G 1 nM 463 1048 0,44179389  T 1 nM 475 828 0,5736715 
Gj.snitt 369,666667 889,333333 0,4131119  Gj.snitt 413,666667 730,333333 0,57009533 
G 10 nM 236 622 0,37942122  T 10 nM 385 617 0,62398703 
G 10 nM 345 769 0,44863459  T 10 nM 469 923 0,50812568 
G 10 nM 407 943 0,43160127  T 10 nM 408 643 0,63452566 
Gj.snitt 329,333333 778 0,42330763  Gj.snitt 420,666667 727,666667 0,58887946 
         
 Luciferase Renilla Ratio   Luciferase Renilla Ratio 
G 0 nM 1025 1941 0,52807831  T 0 nM 867 1363 0,63609685 
G 0 nM 918 1667 0,55068986  T 0 nM 1242 1809 0,68656716 
G 0 nM 807 1462 0,55198358  T 0 nM 1163 1483 0,78422117 
Gj.snitt 916,666667 1690 0,54358392  Gj.snitt 1090,66667 1551,66667 0,70229506 
G 1 nM 746 1397 0,53400143  T 1 nM 1231 1625 0,75753846 
G 1 nM 716 1301 0,55034589  T 1 nM 1220 1480 0,82432432 
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G 1 nM 796 1101 0,72297911  T 1 nM 1060 1856 0,57112069 
Gj.snitt 752,666667 1266,33333 0,60244214  Gj.snitt 1170,33333 1653,66667 0,71766116 
G 10 nM 610 1051 0,58039962  T 10 nM 755 1033 0,73088093 
G 10 nM 848 1594 0,53199498  T 10 nM 1028 1339 0,76773712 
G 10 nM 769 1428 0,53851541  T 10 nM 1197 1471 0,81373215 
Gj.snitt 742,333333 1357,66667 0,54677142  Gj.snitt 993,333333 1281 0,7707834 
 
BEAS-2B 
 Luciferase Renilla Ratio   Luciferase Renilla Ratio 
G 1 nM 18070 912 19,8135965  T 1 nM 10900 637 17,11146 
G 1 nM 16260 991 16,407669  T 1 nM 14650 503 29,1252485 
G 1 nM 14390 898 16,0244989  T 1 nM 22050 942 23,4076433 
Gj.snitt 16240 933,666667 17,4152548  Gj.snitt 15866,6667 694 23,2147839 
G 10 nM 10930 592 18,4628378  T 10 nM 24110 821 29,3666261 
G 10 nM 14210 765 18,5751634  T 10 nM 26090 1590 16,408805 
G 10 nM 12900 788 16,3705584  T 10 nM 19570 837 23,3811231 
Gj.snitt 12680 715 17,8028532  Gj.snitt 23256,6667 1082,66667 23,0521847 
         
 Luciferase Renilla Ratio   Luciferase Renilla Ratio 
G 0 10040 766 13,1070496  T 0 12370 648 19,0895062 
G 0 11120 847 13,1286895  T 0 11940 596 20,033557 
G 0 10570 742 14,245283  T 0 12670 514 24,6498054 
Gj.snitt 10576,6667 785 13,4734607  Gj.snitt 12326,6667 586 21,2576229 
G 1 nM 10000 623 16,0513644  T 1 nM 11000 411 26,7639903 
G 1 nM 9742 616 15,8149351  T 1 nM 11680 574 20,3484321 
G 1 nM 9639 692 13,9291908  T 1 nM 14280 705 20,2553191 
Gj.snitt 9793,66667 643,666667 15,2651634  Gj.snitt 12320 563,333333 22,4559138 
G 10 nM 6023 428 14,0724299  T 10 nM 9826 385 25,5220779 
G 10 nM 8922 601 14,8452579  T 10 nM 12370 554 22,3285199 
G 10 nM 11060 792 13,9646465  T 10 nM 11480 480 23,9166667 
Gj.snitt 8668,33333 607 14,2941114  Gj.snitt 11225,3333 473 23,9224215 
         
 Luciferase Renilla Ratio   Luciferase Renilla Ratio 
G 0 16630 2528 6,57832278  T 0 13580 2018 6,72943508 
G 0 16530 3558 4,64586847  T 0 13090 1454 9,00275103 
G 0 22420 3305 6,78366112  T 0 8364 1142 7,32399299 
Gj.snitt 18526,6667 3130,33333 5,91843254  Gj.snitt 11678 1538 7,68539304 
G 1 nM 12280 2057 5,96985902  T 1 nM 11330 1347 8,41128434 
G 1 nM 14800 2002 7,39260739  T 1 nM 15610 1549 10,0774693 
G 1 nM 18470 2228 8,28994614  T 1 nM 10110 1398 7,23175966 
Gj.snitt 15183,3333 2095,66667 7,21747085  Gj.snitt 12350 1431,33333 8,57350444 
G 10 nM 5384 581 9,26678141  T 10 nM 3702 1172 3,15870307 
G 10 nM 3028 984 3,07723577  T 10 nM 6768 758 8,92875989 
G 10 nM 5515 820 6,72560976  T 10 nM 5067 631 8,03011094 
Gj.snitt 4642,33333 795 6,35654231  Gj.snitt 5179 853,666667 6,70585797 
         
 Luciferase Renilla Ratio   Luciferase Renilla Ratio 
G 0 1220 286 4,26573427  T 0 907 178 5,09550562 
G 0 1497 259 5,77992278  T 0 689 145 4,75172414 
G 0 3159 636 4,96698113  T 0 969 110 8,80909091 
Gj.snitt 1958,66667 393,666667 4,97544454  Gj.snitt 855 144,333333 6,21877355 
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G 1 nM 8510 1635 5,20489297  T 1 nM 8631 1256 6,87181529 
G 1 nM 7606 1520 5,00394737  T 1 nM 6510 1209 5,38461538 
G 1 nM 1216 320 3,8  T 1 nM 6921 1123 6,16295637 
Gj.snitt 5777,33333 1158,33333 4,66961344  Gj.snitt 7354 1196 6,13979568 
G 10 nM 5816 1437 4,04732081  T 10 nM 7646 1250 6,1168 
G 10 nM 2771 762 3,63648294  T 10 nM 5808 790 7,35189873 
G 10 nM 1012 189 5,35449735  T 10 nM 4879 918 5,31481481 
Gj.snitt 3199,66667 796 4,34610037  Gj.snitt 6111 986 6,26117118 
 
BEP-2D 
 Luciferase Renilla Ratio   Luciferase Renilla Ratio 
G 0 nM 4188 520 8,05384615  T 0 nM 1595 227 7,02643172 
G 0 nM 2980 757 3,93659181  T 0 nM 1124 190 5,91578947 
G 0 nM 2526 449 5,62583519  T 0 nM 1413 239 5,91213389 
Gj.snitt 3231,33333 575,333333 5,87209105  Gj.snitt 1377,33333 218,666667 6,28478503 
G 1 nM 3172 433 7,3256351  T 1 nM 2783 466 5,972103 
G 1 nM 3007 463 6,49460043  T 1 nM 3250 433 7,50577367 
G 1 nM 2528 430 5,87906977  T 1 nM 3640 616 5,90909091 
Gj.snitt 2902,33333 442 6,5664351  Gj.snitt 3224,33333 505 6,46232253 
G 10 nM 3346 544 6,15073529  T 10 nM 3103 413 7,51331719 
G 10 nM 3450 488 7,06967213  T 10 nM 2957 406 7,28325123 
G 10 nM 3078 483 6,37267081  T 10 nM 2907 408 7,125 
Gj.snitt 3291,33333 505 6,53102608  Gj.snitt 2989 409 7,30718947 
         
G 0 6399 553 11,5714286  T 0 7022 447 15,7091723 
G 0 5754 487 11,8151951  T 0 7348 486 15,1193416 
G 0 5781 511 11,3131115  T 0 7747 446 17,3699552 
Gj.snitt 5978 517 11,5665784  Gj.snitt 7372,33333 459,666667 16,0661563 
G 1 nM 6215 501 12,4051896  T 1 nM 4939 363 13,6060606 
G 1 nM 6753 521 12,9616123  T 1 nM 6432 468 13,7435897 
G 1 nM 6191 538 11,5074349  T 1 nM 4377 369 11,8617886 
Gj.snitt 6386,33333 520 12,2914123  Gj.snitt 5249,33333 400 13,0704797 
G 10 nM 5710 479 11,9206681  T 10 nM 1952 222 8,79279279 
G 10 nM 5735 468 12,2542735  T 10 nM 7198 472 15,25 
G 10 nM 6336 411 15,4160584  T 10 nM 2706 236 11,4661017 
Gj.snitt 5927 452,666667 13,197  Gj.snitt 3952 310 11,8362982 
         
G 0 10720 819 13,0891331  T 0 12590 709 17,7574048 
G 0 10460 721 14,5076283  T 0 18090 580 31,1896552 
G 0 10600 721 14,7018031  T 0 14620 732 19,9726776 
Gj.snitt 10593,3333 753,666667 14,0995215  Gj.snitt 15100 673,666667 22,9732459 
G 1 nM 8086 554 14,5956679  T 1 nM 8510 498 17,0883534 
G 1 nM 9061 558 16,2383513  T 1 nM 8933 579 15,4283247 
G 1 nM 7817 617 12,6693679  T 1 nM 7084 366 19,3551913 
Gj.snitt 8321,33333 576,333333 14,501129  Gj.snitt 8175,66667 481 17,2906231 
G 10 nM 6527 558 11,6971326  T 10 nM 1011 107 9,44859813 
G 10 nM 5453 447 12,1991051  T 10 nM 1496 95 15,7473684 
G 10 nM 7142 533 13,3996248  T 10 nM 4215 187 22,540107 
Gj.snitt 6374 512,666667 12,4319542  Gj.snitt 2240,66667 129,666667 15,9120245 
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Appendix IV 
The Biobank located at NIOH for lung cancer studies.  
This project is based on the case-control study done (Lind et al) with samples from the Biobank 
located at the National Institute for Occupational Health (NIOH). The cases were 341 
Caucasians born in Norway and of Norwegian origin with newly diagnosed NSCLC which were 
admitted for surgery at the university hospitals in Oslo or Bergen between 1986 and 2001. 
Controls were recruited from a general health survey of the general population conducted by the 
National Health Surveys in the Oslo area (HUBRO) in 2000-2001. The controls in this study 
were selected from this survey based on the following criteria:  (i) they were 59 years of age; (ii) 
had smoked >5 cigarettes per day; and (iii) were current smokers or quit smoking for <5 years. 
Among them, 412 smokers without any known history of cancer were randomly selected and 
frequency matched with the cases on age, smoking dose (pack-years) and male:female ratio. 
From these individuals, blood samples and lung tissue samples have been obtained and used for 
DNA isolation. This DNA has been the basis for the SNP association study by Lind et al as well 
as the C1797G study in this thesis.  
Transcription factors: 
E2F-1 Involved in cell cycle control (G1-S progression), may regulate the action of tumor 
suppressor proteins, binds Rb, can mediate p53 dependent apoptosis and 
proliferation.  
C/EBP Regulates the cell cycle by inducing cell cycle arrest, involved in weight 
homeostasis, regulates genes involved in inflammation and immune responses 
example the IL-1 responsive element on IL-6, can stimulate the expression of 
collagen type I.  
p53 Involved in cell cycle control, apoptosis and genetic stability.  
Sp1 A general transcription factor. May be involved in the axis development (anterior-
posterior etc), organogenesis, differentiation and tissue growth. 
Pax-5 Regulates early development and alterations in regulation promotes neoplastic 
lesions.  
GCF Repressor that binds GC-rich sequences. May regulate the expression of tumor 
necrosis factors and epidermal growth factor receptors.  
Egr-1 Early growth response-1 is involved in differentiation and mitogenesis. Might be a 
cancer suppressor.  
ETF Participates in catalyzing the initial step of the mitochondrial fatty acid beta-
oxidation. It shuttles electrons between primary flavoprotein dehydrogenases and 
the membrane-bound electron transfer flavoprotein ubiquinone oxidoreductase. 
Oct-1 Transcription factor that binds to the octamer motif (5'-ATTTGCAT-3') and 
activates the promoters of the genes for some small nuclear RNAs (snRNA) and of 
genes such as those for histone H2B and immunoglobulins. 
NF-muE1 Multifunctional transcription factor that exhibits positive and negative control on 
a large number of cellular and viral genes by binding to sites overlapping the 
transcription start site. May play an important role in development and 
differentiation. 
c-Myc Participates in the regulation of gene transcription. Binds DNA both in a non-
specific manner and also specifically to recognizes the core sequence 5'-
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CAC[GA]TG-3'. Seems to activate the transcription of growth-related genes. 
AP-2alph Sequence-specific DNA-binding protein that interacts with inducible viral and 
cellular enhancer elements to regulate transcription of selected genes. AP-2 
factors bind to the consensus sequence 5'-GCCNNNGGC-3' and activate genes 
involved in a large spectrum of important biological functions including proper 
eye, face, body wall, limb and neural tube development.  
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Appendix V 
SNP309 association studies and their outcomes.  
Authors Tissue Other findings 
Risk 
association 
with SNP309 
Population 
K. Mittelstrass et 
al [82] 
Lung Possibly earlier age of onset 
for women. 
No Caucasian 
X. Zhang et al [83] Lung Also association with SNP 
p53 Arg72Pro 
Yes Han Chinese 
Z. Hu et al [73] Lung  No Chinese 
S. Pine et al [84] Lung Also no association with 
MDM2 SNP354 
No African-
American 
Caucasian 
Lind et al [57] Lung 
NSCLC 
Especially association with 
women.                       
Mutations in p53 associated 
with higher age of diagnosis 
Yes Caucasian 
H. J. Jun et al [85] Lung P73 SNP G4C14 – A4T14 
also associated with risk.                 
In addition an additive 
effect between the SNPs. 
Yes Korean 
G. Liu et al [86] Lung 
NSCLC 
 Yes in 
never/light 
smokers 
Caucasian 
G. Li  et al [76] Lung Protective function G allele? 
Higher risk with TT 
genotype (especially males). 
No Caucasian 
J. Han et al [75] Lung 
NSCLC 
Clinical outcome of NSCLC. 
Shorter overall survival 
time. SNP p53 codon 72 
gave a worse clinical 
outcome. 
Yes Korean 
M. Ruijs et al [87] Any 
primary 
tumor 
Li Fraumeni patients.       
Earlier age of onset. 
Yes Dutch Finnish 
V. Galic et al [66] Ovarian SNP p53 codon 72 alone 
associated with shorter 
survival. 
No Caucasian 
Peritoneal SNP p53 codon 72 alone 
associated with shorter 
No Caucasian 
Appendix 
103 
 
survival. 
G. Bond et al [81] Diffuse 
large B-cell 
lymphoma 
Earlier age of onset for ER 
positive tumor patients. 
No Caucasian 
(Ashkenazi 
Jewish) 
Breast 
(invasive 
ductal) 
Earlier age of onset in 
patients with ER positive 
tumors. 
No Caucasian 
(Ashkenazi 
Jewish) 
Soft tissue 
sarcoma 
Earlier age of onset. No Caucasian 
R. Stoehr et al [88] Prostate  No German 
B. Talseth et al 
[70] 
Colorectal Age of onset in individuals 
with hereditary 
nonpolyposis colorectal 
cancer. 
No Australian 
Polish 
G. Bond et al [65] Colorectal Earlier age of onset in 
women. 
No Italian 
Finnish 
D. Krekac et al [67] Breast  No Czech 
C. Walsh et al [72] Endometria
l 
 Yes Caucasian 
African-
American 
Hispanic 
Asian 
P. Alhopuro et al 
[64] 
Uterine  No Finnish 
Colorectal Earlier age of onset in 
women. 
No 
Head and 
neck 
 No 
N. Dharel et al [89] Liver Patients with hepatitis C. Yes Japanese 
H. Tsuiki et al [90] Glioma  No Japanese 
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Appendix VI 
Odds ratio 
Odds ratio can be defined as the ratio between the odds of a certain happening in one group and 
the odds for the same happening in another group [60].  
The equation for odds ratio calculation is shown below.  
 
Linear regression 
A regression analysis will study the relationship between 2 variables where one is dependent 
and the other is explanatory/independent. Linear regression gives the regression line function as 
shown in equation 1. 
 
Here b describes how much the y-value will change with one unit difference in x. This function is 
not accurately fulfilled, but an estimated function is satisfied and shown in equation 2. 
 
Here ε indicates the individual variation and is the difference between the estimated line value 
and the actual observation.  
To find the regression line the method of least squares is employed. For the number of 
individual xi and yi values the means are calculated (x and y) and put into equation 3.  
 
The b value can be further calculated shown in equation 4. 
 
Here b is called the regression coefficient. These estimated values are then used in equation 1. 
Also the R2 value can be calculated and this is the Pearson’s coefficient of regression. This 
coefficient is closely related to the regression coefficient b described in equation 4. Pearson’s 
coefficient will be used with normally distributed data and will vary between -1 and 1 for 
negative and positive correlation, respectively. It describes the strength and direction of the 
linear relationship between the two variables and how much variation there is around the 
regression line. For an increasing regression line the value should be as close as possible to 1 
because of the positive correlation. A value closer to 0 will indicate no linear relationship 
between the variables [60].  
T-test 
The T-test (Student T-test) is used to study the differences in means or medians in a group of 
observations. There are two types of this test: paired T-test and T-test. The T-test can be used to 
conclude on observations in one group or in two groups. Two groups of data can be analyzed as 
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one (paired T-test) but the data must then be related and the difference between observations 
must be calculated.  
An example where the paired T-test can be used is when measuring blood pressure before and 
after treatment in the same patient. The difference between reading 1 and reading 2 is 
calculated. If deviation from 0 is found in addition to a p-value below 0,05 the null hypothesis is 
rejected. The equation used is shown in equation 5.  
 
In equation 5 d is the mean of the calculated differences in the measurements, s is the standard 
deviation in the differences calculated and n is the number of subjects used.  
An example where the T-test is used is during the comparison of two independent groups of 
data. The data must be normally distributed in addition to the assumption that the standard 
deviations in the two groups are approximately the same. The null hypothesis is that there is no 
difference between the two groups. The means of the two groups are calculated and put into 
equation 6.  
 
Here X is the mean of group 1 and 2 respectively, s the standard deviation and n the number of 
observations in group 1 and 2 respectively.  
The standard deviation, assumed alike in the two groups, is calculated from equation 7.  
 
This test can be used for example when analyzing the same parameter, but in different subject 
groups. Again, if the t-value deviates from 0 and the p-value is below 0,05 the null hypothesis is 
rejected [60].  
In this thesis standard error has been chosen to be included in the graphs. Standard error is the 
standard deviation of the different measurements deviation from the expected value. It is often 
used with the T-test to provide a confidence interval for an estimated mean or difference of 
means. It can also provide an indication of the uncertainty and its size. Standard deviation is a 
measurement of the distribution of a datasample’s values, the deviation from the value’s mean, 
an estimate of the variability of the population from which the sample was drawn. When the 
data is normally distributes 95 % of the individuals will have values within 2 standard 
deviations from the mean. The standard error of the sample mean depends on both the standard  
deviation and the sample size and can be described as SE = SD/ (sample size). The standard 
error falls as the sample size increases since the chance variation is reduced. By contrast the 
standard deviation will not tend to change as we increase the size of our sample [91]. 
Logistic regression analysis (SNP association study) 
The logistic regression function follows the equation 9 where z may be any number both positive 
and negative infinitely whereas the f(z) varies between 0 and 1.  
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z represents the exposure to risk factors and f(z) is the probability of a certain outcome.  
 
βk is the regression coefficient of xk. A positive regression coefficient indicates that the risk factor 
increases the probability of the outcome.  
The application of a logistic regression may be illustrated using a fictitious example of death 
from heart disease. This simplified model uses only three risk factors (age, sex, and blood 
cholesterol level) to predict the 10-year risk of death from heart disease. This is the model that 
we fit: 
β0 = − 5.0 (the intercept) 
β1 = + 2.0 
β2 = − 1.0 
β3 = + 1.2 
x1 = age in decades, less 5.0 
x2 = sex, where 0 is male and 1 is female 
x3 = cholesterol level, in mmol/L less 5.0 
Which means the model is: 
 
In this model, increasing age is associated with an increasing risk of death from heart disease (z 
goes up by 2.0 for every 10 years over the age of 50), female sex is associated with a decreased 
risk of death from heart disease (z goes down by 1.0 if the patient is female), and increasing 
cholesterol is associated with an increasing risk of death (z goes up by 1.2 for each 1 mmol/L 
increase in cholesterol above 5mmol/L) [60]. 
The outcome of a logistic regression is the odds ratio which helps to elucidate the factors with 
the greatest importance in the outcome one is studying. The confidence interval indicate the 
statistical significance of the predicted odds ratio [92].  
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